$45.83
+0.86 (+1.91%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where SNY is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
Of the 500 shown: 418 interventional · 82 observational · 133 with posted results
Held by 17 tracked-famous managers (Dodge & Cox, MILLENNIUM MANAGEMENT LLC, Balyasny Asset Management L.P., CITADEL ADVISORS LLC, Point72 Asset Management, L.P., +12 more) · FINRA short interest 2.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Registry for Stage 2 Type 1 DiabetesNCT06481904observationalNumber of adverse events of special interests (AESI) | — | Recruiting | Drug: TZIELD (teplizumab-mzwv) | Type 1 Diabetes | 200 | 2037-01-15 | in 3,801 d | 2026-04-13 |
| Long-Term Outcomes of Teplizumab in Routine Clinical CareNCT07360080observationalTime from teplizumab infusion start to the onset of Stage 3 T1D | — | Recruiting | Drug: Teplizumab | Type 1 Diabetes | 1,000 | 2035-10-29 | in 3,357 d | 2026-05-27 |
| Observational Evaluation of Atopic Dermatitis in Pediatric PatientsNCT03687359observationalPatient demographics | — | Active, not recruiting | Other: Standard of care | Dermatitis Atopic | 1,860 | 2035-07-23 | in 3,259 d | 2025-08-15 |
| This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic TreatmentNCT07290803observationalNumber of Participants Utilizing Atopic Dermatitis (AD) Treatment | — | Recruiting | — | Atopic Dermatitis | 1,000 | 2034-01-30 | in 2,720 d | 2026-08-06 |
| Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular DegenerationNCT01736592The incidence of Adverse EventsOpen-label · Other | Phase 2 | Active, not recruiting | Drug: Long term follow up in all patients who received SAR422459 in previous study TDU13583 | Stargardt's Disease | 27 | 2033-08-29 | in 2,566 d | 2025-06-12 |
| Avalglucosidase Alfa Pregnancy StudyNCT05734521observationalMaternal complications | — | Recruiting | Biological: avalglucosidase alfa-NGPT (GZ402666) IV, avalglucosidase alfa-NGPT (GZ402666) | Pompe Disease, Pregnancy | 100 | 2032-10-31 | in 2,264 d | 2026-01-16 |
| A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in TaiwanNCT06684314observationalChange from baseline in total scores of the Hemophilia Joint Health Score (HJHS) for all joints | — | Recruiting | Drug: Efanesoctocog alfa | Hemophilia A | 100 | 2031-08-28 | in 1,834 d | 2025-10-02 |
| A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1BNCT02065011The incidence of adverse eventsOpen-label · Other | Phase 2 | Active, not recruiting | Drug: Blood draw for the laboratory assessment | Usher's Syndrome | 9 | 2031-06-13 | in 1,758 d | 2026-01-13 |
| Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic DermatitisNCT05769777Percentage of participants who experienced Treatment-Emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Amlitelimab | Dermatitis Atopic | 999 | 2031-06-11 | in 1,756 d | 2026-04-23 |
| A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory MyelomaNCT06630806Incidence of Dose Limiting Toxicities (DLTs)- Dose escalation (Part A)Randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: SAR446523 | Plasma Cell Myeloma Refractory | 87 | 2031-05-16 | in 1,730 d | 2026-03-25 |
| Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical StudyNCT06914908Incidence of participants with treatment-emergent adverse events (TEAEs) including adverse events of special interest (AESI), and serious adverse events (SAEs)Open-label · Treatment | Phase 2 | Enrolling by invitation | Drug: Lunsekimig, Mometasone furoate nasal spray (MFNS) | Chronic Rhinosinusitis With Nasal Polyps | 71 | 2031-01-29 | in 1,623 d | 2026-07-02 |
| Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With AsthmaNCT06609239Exposure-adjusted incidence rate of treatment-emergent adverse event (TEAE), including adverse events of special interest (AESI), and serious adverse event (SAE)Open-label · Treatment | Phase 2 | Enrolling by invitation | Drug: Lunsekimig | Asthma | 900 | 2031-01-20 | in 1,614 d | 2026-08-13 |
| A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United StatesNCT07260110observationalChange in participant and caregiver-reported outcomes from survey responses: ease of diabetes management questions | — | Recruiting | Drug: Teplizumab | Type 1 Diabetes | 550 | 2030-12-03 | in 1,566 d | 2025-12-03 |
| Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple MyelomaNCT04270409Number of participants with Treatment-emergent adverse events (AEs) and serious adverse events- Safety Run-in PartRandomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Isatuximab SAR650984, Lenalidomide, Dexamethasone, Montelukast or equivalent, Acetaminophen, Diphenhydramine or equivalent, Methylprednisolone or equivalent | Plasma Cell Myeloma | 337 | 2030-10-14 | in 1,516 d | 2025-12-12 |
| Long-term Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported OutcomesNCT07380711observationalDescriptive statistical analysis of socio-demographics | — | Recruiting | — | Chronic Obstructive Pulmonary Disease COPD | 500 | 2030-08-14 | in 1,455 d | 2026-04-14 |
| A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)NCT07222189Number of participants with Crohn's Disease with treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs)Non-randomized · Quadruple-masked · Treatment | Phase 2 | Enrolling by invitation | Drug: balinatunfib, balinatunfib-matching placebo | Colitis Ulcerative, Crohn's Disease | 325 | 2030-05-10 | in 1,359 d | 2026-05-22 |
| A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With PhenylketonuriaNCT05972629Incidence of treatment-emergent adverse events (TEAEs)Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: SAR444836 | Phenylketonuria | 32 | 2030-04-02 | in 1,321 d | 2025-09-23 |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic PhenotypeNCT07190209Annualized rate of moderate-to-severe chronic obstructive pulmonary disease (COPD) exacerbationsRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Lunsekimig, Placebo | Chronic Obstructive Pulmonary Disease | 942 | 2029-11-27 | in 1,195 d | 2026-06-15 |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic PhenotypeNCT07190222Annualized rate of moderate-to-severe chronic obstructive pulmonary disease (COPD) exacerbationsRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Lunsekimig, Placebo | Chronic Obstructive Pulmonary Disease | 942 | 2029-11-27 | in 1,195 d | 2026-06-15 |
| Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDPNCT06859099Number of participants having any AEs, SAEs, adverse events leading to treatment discontinuation, AESIs, and potentially clinically significant abnormalities (PCSAs) in safety laboratory tests, ECGs, and vital signs during the study periodOpen-label · Treatment | Phase 3 | Enrolling by invitation | Drug: Riliprubart Prefilled Pen (PFP) | Polyneuropathy, Inflammatory Demyelinating, Chronic | 300 | 2029-10-03 | in 1,140 d | 2026-07-13 |
| A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of KoreaNCT07200206observationalOccurence of Adverse Events (AEs) | — | Recruiting | Biological: Nirsevimab | Respiratory Syncytial Virus | 3,000 | 2029-09-26 | in 1,133 d | 2025-12-03 |
| A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host DiseaseNCT07771439Overall response rateRandomized · Open-label · Treatment | Phase 3 | Not yet recruiting | Drug: Belumosudil · Other: Best available therapy (BAT) | Chronic Graft Versus Host Disease | 356 | 2029-09-14 | in 1,121 d | 2026-08-18 |
| A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney TransplantationNCT07412470Composite efficacy failure rate (BPAR, graft loss, and death) by 1 year post kidney transplantationRandomized · Open-label · Treatment | Phase 2/3 | Recruiting | Drug: Frexalimab, Frexalimab, Tacrolimus, rabbit anti-thymocyte globulin, mycophenolate mofetil, mycophenolate sodium, methylprednisolone, prednisone | Kidney Transplant Rejection | 526 | 2029-08-15 | in 1,091 d | 2026-06-23 |
| A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's DiseaseNCT07184944Co-primary endpoints US/FDA: Pivotal Maintenance Sub-Study Cohort 1 Proportion of participants achieving clinical remission (CDAI) at Week 40Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Duvakitug, Placebo | Crohn's Disease | 751 | 2029-08-13 | in 1,089 d | 2026-06-22 |
| A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or BNCT07285460Annualized treated bleeding rate (ABR) in the fitusiran primary efficacy period and in the SOC periodOpen-label · Treatment | Phase 3 | Recruiting | Drug: Fitusiran · Biological: Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC) | Hemophilia | 85 | 2029-08-04 | in 1,080 d | 2026-08-17 |
| A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's DiseaseNCT07688213Part A and optional dose 2 cohort: change from baseline to Week 48 in plasma p-tau217Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: SAR448851, Placebo | Dementia, Alzheimer's Type, Alzheimer's Disease | 160 | 2029-07-31 | in 1,076 d | 2026-08-10 |
| Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world ConditionsNCT07052396observationalChange from Baseline in COPD Assessment Test (CAT) Score | — | Recruiting | Drug: Dupilumab | Chronic Obstructive Pulmonary Disease (COPD) | 350 | 2029-07-01 | in 1,046 d | 2025-12-22 |
| The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) RegistryNCT07612878observationalParticipant Characteristics | — | Not yet recruiting | Drug: Cohort 1: Dupilumab · Other: Cohort 2: usual care only | COPD (Chronic Obstructive Pulmonary Disease) | 350 | 2029-06-30 | in 1,045 d | 2026-07-02 |
| A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic DiseasesNCT06647069Incidence of treatment-emergent adverse events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: SAR448501 | Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA) | 62 | 2029-06-25 | in 1,040 d | 2026-05-22 |
| Sarilumab Efficacy and Safety in Adults With Early Polymyalgia RheumaticaNCT07286214Sustained remission at Week 52 (yes/no) in participants with early relapsing polymyalgia rheumatica (PMR) who received sarilumab 200 mg q2w with 52-week prednisone taperRandomized · Quadruple-masked · Treatment | Phase 4 | Recruiting | Drug: Sarilumab, Sarilumab, Placebo | Polymyalgia Rheumatica | 300 | 2029-06-04 | in 1,019 d | 2026-06-23 |
| An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's DiseaseNCT07184931Sub-Study 2: Co-primary endpoints US/FDA: Proportion of participants achieving clinical remission per Crohn's Disease Activity Index (CDAI) at Week 12Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Duvakitug, Placebo | Crohn's Disease | 980 | 2029-05-14 | in 998 d | 2026-07-01 |
| A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.NCT06372145Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs) and AEs leading to permanent study intervention discontinuationNon-randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Tolebrutinib, Placebo, Teriflunomide | Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis | 2,500 | 2029-04-30 | in 984 d | 2026-08-17 |
| A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical PracticeNCT07556159observationalPart 1: Descriptive Characterization of Participants With Asthma Across the Spectrum of Severities | — | Recruiting | Other: Procedure: Investigational Procedures, Procedure: Investigational Procedures | Asthma | 2,500 | 2029-04-04 | in 958 d | 2026-08-13 |
| A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1NCT06844214Part A and Part B: Incidence of treatment-emergent adverse events (TEAEs) following SAR446268 administrationOpen-label · Treatment | Phase 1/2 | Recruiting | Biological: SAR446268 | Myotonic Dystrophy | 32 | 2029-02-28 | in 923 d | 2026-06-01 |
| Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled SyringeNCT07282795observationalOccurrence of solicited injected site reactions. | — | Not yet recruiting | Biological: Efluelda® Pre-filled syringe | Influenza Immunization, Healthy Volunteers | 670 | 2029-02-22 | in 917 d | 2026-03-31 |
| A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft DysfunctionNCT06082037Percent change from baseline to Week 26 in forced expiratory volume in 1 second (FEV1)Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Belumosudil, Azithromycin, Placebo | Lung Transplant Rejection | 180 | 2029-01-29 | in 893 d | 2026-06-29 |
| Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical TrialsNCT05492578Percentage of participants who experienced treatment-emergent adverse event (TEAE)Non-randomized · Open-label · Treatment | Phase 2/3 | Enrolling by invitation | Drug: Amlitelimab, Topical corticosteroids, Topical calcineurin inhibitors, Oral corticosteroids | Dermatitis Atopic | 1,663 | 2029-01-22 | in 886 d | 2026-07-02 |
| A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)NCT06192576observationalNumber of cases in the exposed population with AEs, SAEs, and AESIs (including moderate/severe or recurrent hypersensitivity reactions and infusion-associated reactions) | — | Recruiting | Drug: Olipudase alfa | Niemann-Pick Diseases, Acid Sphingomyelinase Deficiency | 10 | 2029-01-02 | in 866 d | 2025-10-31 |
| A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.NCT07053423Change from baseline to Week 24 in global lung mucus score (UCSF mucus scoring)Randomized · Quadruple-masked · Treatment | Phase 4 | Recruiting | Drug: Dupilumab, Placebo | Chronic Obstructive Pulmonary Disease | 218 | 2028-12-23 | in 856 d | 2026-06-12 |
| Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)NCT06191315Part A: Annualized rate of severe asthma exacerbations during the 52-week treatment periodRandomized · Triple-masked · Treatment | Phase 3 | Enrolling by invitation | Drug: Dupilumab, Placebo | Wheezing, Asthma | 90 | 2028-12-21 | in 854 d | 2026-08-13 |
| International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From IsatuximabNCT05669989Number of participants with treatment-emergent adverse eventsOpen-label · Treatment | Phase 2 | Enrolling by invitation | Drug: Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone, Lenalidomide, Pomalidomide, Isatuximab subcutaneous (SC), Carfilzomib | Plasma Cell Myeloma | 70 | 2028-11-30 | in 833 d | 2026-07-31 |
| Phase 1b/2 Study of IV Sarilumab in Adult With RANCT07704580Part A: Assessment of Pharmacokinetic (PK) parameters of sarilumab in serum: area under the concentration-time curve [AUClast] for IV dosesRandomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Sarilumab, SAR153191 SC, Sarilumab, SAR153191 IV | Rheumatoid Arthritis | 140 | 2028-10-26 | in 798 d | 2026-08-11 |
| A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.NCT06143891Event-Free Survival (EFS)Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Belumosudil, Placebo, Prednisone, Prednisolone | Chronic Graft Versus Host Disease | 260 | 2028-09-29 | in 771 d | 2025-10-14 |
| A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)NCT07116031Phase 1: AUCOpen-label · Treatment | Phase 2 | Recruiting | Drug: Belumosudil, Belumosudil | Chronic Graft Versus Host Disease | 37 | 2028-09-25 | in 767 d | 2026-06-05 |
| A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative ColitisNCT07185009Pivotal Maintenance Sub-Study Cohort 1: Proportion of participants achieving clinical remission by modified Mayo Score (mMS).Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Duvakitug, Placebo | Ulcerative Colitis | 751 | 2028-09-21 | in 763 d | 2026-08-18 |
| A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction CancerNCT07692204Objective response rateRandomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: SAR445877 | Gastric Cancer, Oesophageal Carcinoma | 30 | 2028-08-02 | in 713 d | 2026-07-20 |
| Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency EmphysemaNCT05897424Long-term safety and tolerabilityOpen-label · Treatment | Phase 2 | Active, not recruiting | Drug: SAR447537 | Alpha 1-Antitrypsin Deficiency, Emphysema | 185 | 2028-06-30 | in 680 d | 2026-04-13 |
| A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related DiseaseNCT07190196Time to first adjudicated clinical disease flare treated by the investigator during the Blinded Treatment periodRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Rilzabrutinib, Placebo, Glucocorticoid | Immunoglobulin G4 Related Disease | 124 | 2028-06-28 | in 678 d | 2026-07-28 |
| A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia ANCT05911763observationalChange from baseline in Annualized joint bleeding rate (AjBR) for treated bleeds | — | Active, not recruiting | Drug: Efanesoctocog Alfa BIVV001 | Hemophilia A | 200 | 2028-06-06 | in 656 d | 2025-10-02 |
| A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 DiabetesNCT07088068For United States (US) and non-European Union (EU) countries: Glycated hemoglobin (HbA1c) change from baselineRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Teplizumab · Other: Placebo | Type 1 Diabetes Mellitus | 723 | 2028-06-06 | in 656 d | 2026-08-10 |
| A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic AnemiaNCT07086976Proportion of participants achieving DHR. DHR is defined as an increase of Hb by ≥2 g/dL from baseline on at least two thirds of evaluable scheduled visits between Week 12 and Week 24 (inclusive) in the PAPRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: rilzabrutinib, placebo | Autoimmune Haemolytic Anaemia | 90 | 2028-05-31 | in 650 d | 2026-06-04 |
| A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With EmicizumabNCT06145373Number of participants with Adverse events (AEs) during the fitusiran treatmentOpen-label · Treatment | Phase 4 | Recruiting | Drug: Fitusiran (SAR439774) · Biological: Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC), Emicizumab | Hemophilia A | 20 | 2028-05-28 | in 647 d | 2026-06-02 |
| A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving DupilumabNCT06169527observationalDemographic characteristics of participants who receive dupilumab for AD | — | Active, not recruiting | Drug: Dupilumab | Atopic Dermatitis | 303 | 2028-05-10 | in 629 d | 2025-07-14 |
| An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative ColitisNCT07184996Proportion of participants achieving clinical remission.Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Duvakitug, Placebo | Ulcerative Colitis | 980 | 2028-05-09 | in 628 d | 2026-04-24 |
| Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and OlderNCT07734649RSV A serum nAb (neutralizing antibodies) titersRandomized · Triple-masked · Prevention | Phase 1/2 | Recruiting | Biological: RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4, Control Vaccine 2, Control Vaccine 1 · Other: Placebo | Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers | 2,400 | 2028-05-03 | in 622 d | 2026-07-29 |
| A Study to Observe How Pediatric Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions Respond to Dupilumab TreatmentNCT06192563observationalChildren and Adolescents: Percentage (%) change from baseline in Eczema Area and Severity Index (EASI) score | — | Recruiting | Drug: Dupilumab | Atopic Dermatitis | 230 | 2028-03-31 | in 589 d | 2026-08-13 |
| Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple SclerosisNCT06141486Time to onset of composite confirmed disability progression (cCDP) confirmed over 6 months in the double-blind treatment periodRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Frexalimab, Placebo, MRI contrast-enhancing agents | Multiple Sclerosis | 943 | 2028-03-24 | in 582 d | 2026-05-14 |
| Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in ChinaNCT07710872Participants 12 through 23 MoA (Cohort I): Vaccine seroresponse to meningococcal serogroups A, C, Y, and WRandomized · Quadruple-masked · Prevention | Phase 3 | Not yet recruiting | Biological: MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA), Menhycia® (ACYW135 Meningococcal Conjugate Vaccine [CRM197]) (CanSino Biologics Inc., China) | Meningococcal Infection, Healthy Volunteers | 4,568 | 2028-03-13 | in 571 d | 2026-07-17 |
| Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic DermatitisNCT06039241observationalNumber of patients who maintain Eczema Area and Severity Index (EASI) ≤ 7 OR peak pruritus Numerical Rating Scale (NRS) ≤ 4 OR Dermatology Life Quality Index (DLQI) ≤ 5 | — | Recruiting | — | Atopic Dermatitis | 900 | 2028-03-08 | in 566 d | 2026-02-12 |
| Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 DiabetesNCT06791291Number of participants with Stage 3 Type 1 Diabetes based on American Diabetes Association criteriaRandomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Teplizumab | Type 1 Diabetes Mellitus | 10 | 2028-03-06 | in 564 d | 2026-07-01 |
| A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)NCT02991469Assessment of PK parameter: maximum serum concentration observed (Cmax)Open-label · Treatment | Phase 2 | Recruiting | Drug: Sarilumab SAR153191 (REGN88) | Juvenile Idiopathic Arthritis | 51 | 2028-03-01 | in 559 d | 2026-05-22 |
| SAR447971 First-in-human StudyNCT07629336SAD20411: Incidence of treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Recruiting | Drug: SAR447971, Placebo | Hidradenitis, Healthy Volunteers | 114 | 2028-02-16 | in 545 d | 2026-06-05 |
| A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin LymphomaNCT06392477Incidence of treatment-emergent adverse event (TEAE)Open-label · Treatment | Phase 1 | Recruiting | Drug: SAR448501 | B-cell Non Hodgkin Lymphoma | 96 | 2028-01-21 | in 519 d | 2025-12-23 |
| Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 YearsNCT06891417Presence of immediate unsolicited systemic adverse events (AEs)Randomized · Triple-masked · Prevention | Phase 1/2 | Recruiting | Biological: Chlamydia mRNA Vaccine · Other: Placebo | Chlamydia Trachomatis Immunization | 1,560 | 2028-01-03 | in 501 d | 2026-04-08 |
| Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe.NCT06694025observationalOccurrence of solicited (pre-listed in the participant's diary card [DC] and case report form) injection site and systemic reactions | — | Not yet recruiting | Biological: Efluelda Tetra Pre-filled syringe | Immunization, Influenza (Healthy Volunteers) | 670 | 2027-12-31 | in 498 d | 2025-12-15 |
| Post Marketing Surveillance Study for MenQuadfi® [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of KoreaNCT07621653observationalNumber of participants with solicited injection site and systemic reactions | — | Recruiting | Biological: Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine | Meningococcal Immunization, Healthy Volunteers | 706 | 2027-11-23 | in 460 d | 2026-07-29 |
| Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line TreatmentNCT07007962Durable platelet responseOpen-label · Treatment | Phase 3 | Recruiting | Drug: rilzabrutinib | Immune Thrombocytopenia | 60 | 2027-11-05 | in 442 d | 2026-06-22 |
| A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo NodularisNCT06293053Concentration of dupilumab in serumOpen-label · Treatment | Phase 3 | Recruiting | Drug: Dupilumab | Prurigo Nodularis | 18 | 2027-10-28 | in 434 d | 2026-01-15 |
| Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophyNCT06941870Proportion of joints with improvement in the Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) synovitis domain scoreNon-randomized · Open-label · Treatment | Phase 4 | Recruiting | Drug: Efanesoctocog alfa | Factor VIII Deficiency | 35 | 2027-10-25 | in 431 d | 2025-11-18 |
| Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeNCT06824194Presence of any immediate adverse events (AEs)Randomized · Quadruple-masked · Prevention | Phase 3 | Active, not recruiting | Biological: PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix | Pneumococcal Immunization | 2,360 | 2027-10-22 | in 428 d | 2026-04-13 |
| A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular DegenerationNCT07215234Incidence and severity of ocular and non-ocular treatment-emergent adverse events (TEAEs)Randomized · Double-masked · Treatment | Phase 1/2 | Recruiting | Drug: SAR446597, Sham Comparator | Geographic Atrophy | 104 | 2027-10-13 | in 419 d | 2026-07-01 |
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK InhibitorNCT06241118EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 36Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Amlitelimab, Placebo, Topical corticosteroids, Topical tacrolimus or pimecrolimus | Dermatitis Atopic | 636 | 2027-09-30 | in 406 d | 2026-07-02 |
| A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis SuppurativaNCT07225569Percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: SAR445399, Placebo | Hidradenitis Suppurativa | 144 | 2027-09-22 | in 398 d | 2026-07-01 |
| Isatuximab in Combination With Novel Agents in RRMM - Master ProtocolNCT04643002Part 1 (dose finding, experimental substudies): Determination of recommended dose of novel agents in combination with isatuximabRandomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: Isatuximab, Dexamethasone, Pomalidomide, Belantamab mafodotin, Pegenzileukin, SAR439459, Belumosudil, Evorpacept | Plasma Cell Myeloma Refractory | 258 | 2027-09-13 | in 389 d | 2026-06-16 |
| Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeNCT06824181Presence of any immediate adverse events (AEs)Randomized · Quadruple-masked · Prevention | Phase 3 | Active, not recruiting | Biological: PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix | Pneumococcal Immunization | 580 | 2027-09-10 | in 386 d | 2026-02-13 |
| A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)NCT07135973Drug related Grade ≥ 3 treatment emergent adverse events (TEAE)Open-label · Treatment | Phase 4 | Not yet recruiting | Drug: Belumosudil | Chronic Graft Versus Host Disease | 26 | 2027-08-30 | in 375 d | 2026-05-12 |
| Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeNCT06975878Seroresponse rate for PCV21 and 15vPCV serotypesRandomized · Quadruple-masked · Prevention | Phase 3 | Active, not recruiting | Biological: PCV21 vaccine, Vaxneuvance vaccine, Hexyon vaccine, M-M-RvaxPro vaccine, Varivax vaccine | Pneumococcal Immunization, Healthy Volunteers | 1,092 | 2027-08-25 | in 370 d | 2026-03-02 |
| Brivekimig for the Treatment of Moderate to Severe Hidradenitis SuppurativaNCT07170917Percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: Brivekimig, Placebo | Hidradenitis Suppurativa | 208 | 2027-08-01 | in 346 d | 2026-06-12 |
| A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative ColitisNCT06867094Proportion of participants achieving clinical remission at Week 12 by modified Mayo Score (mMS)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: SAR441566, SAR441566 matching Placebo | Colitis Ulcerative | 204 | 2027-07-29 | in 343 d | 2026-06-23 |
| The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell DiseaseNCT06975865Annualized rate of clinical VOCRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Rilzabrutinib, Placebo | Sickle Cell Disease | 192 | 2027-07-23 | in 337 d | 2026-07-29 |
| A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.NCT06637631Proportion of participants achieving endoscopic responseRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: SAR441566, SAR441566 matching Placebo | Crohn's Disease | 260 | 2027-07-21 | in 335 d | 2026-06-12 |
| Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple SclerosisNCT07325292Area under the curve over the interval W20 to W24(part A)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Frexalimab, Frexalimab, MRI contrast-enhancing preparations | Multiple Sclerosis | 160 | 2027-07-15 | in 329 d | 2026-08-14 |
| A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)NCT06290141Percentage of participants experiencing a responseRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: riliprubart, Placebo, riliprubart, Placebo, IVIg, Placebo | Chronic Inflammatory Demyelinating Polyneuropathy | 160 | 2027-07-09 | in 323 d | 2026-07-29 |
| Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk AsthmaNCT06676319Annualized rate of asthma exacerbation eventsRandomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Lunsekimig, Short-Acting Beta Agonists (SABA), Placebo, Fluticasone/Salmeterol, Budesonide/Formoterol, Budesonide/Albuterol | Asthma | 556 | 2027-06-21 | in 305 d | 2026-07-01 |
| Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of AgeNCT07348692For all participants: Serotype specific Immunoglobulin g (IgG) Geometric Mean Concentration (GMC)Randomized · Quadruple-masked · Prevention | Phase 3 | Recruiting | Biological: PCV21 vaccine, 20vPCV licensed vaccine | Pneumococcal Immunization, Healthy Volunteers | 2,195 | 2027-06-07 | in 291 d | 2026-05-22 |
| Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)NCT05263206Study A: Proportion of participants with improvement (reduction) in weekly average of daily worst-itch numerical rating scale (WI-NRS) by ≥4 from baseline to Week 24Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Dupilumab, Placebo, Fexofenadine (loratadine if not available) | Pruritus | 284 | 2027-06-02 | in 286 d | 2026-07-06 |
| A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in GermanyNCT06695897observationalDescriptive statistical analysis of medical history characteristics | — | Recruiting | Drug: Dupilumab | Eosinophilic Esophagitis | 150 | 2027-06-01 | in 285 d | 2026-03-06 |
| The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic DermatitisNCT07467564observationalProportion of Participants with Hospital Anxiety and Depression Scale Anxiety (HADS-A) Sub-scores of Less Than 8 | — | Recruiting | Drug: Dupilumab | Atopic Dermatitis | 184 | 2027-05-24 | in 277 d | 2026-07-28 |
| A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular DegenerationNCT06660667Incidence and severity of ocular treatment emergent adverse event (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1/2 | Active, not recruiting | Biological: SAR402663 · Drug: Diluent | Neovascular Age-related Macular Degeneration | 66 | 2027-05-18 | in 271 d | 2026-07-16 |
| Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)NCT06968975observationalI-RODS score at baseline | — | Recruiting | — | Polyneuropathy, Inflammatory Demyelinating, Chronic | 200 | 2027-05-17 | in 270 d | 2026-07-24 |
| French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)NCT06837454observationalPrevious and Current Treatments for Atopic Dermatitis (AD) | — | Recruiting | — | Atopic Dermatitis | 600 | 2027-05-13 | in 266 d | 2026-05-20 |
| Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisNCT06141473Annualized relapse rate (ARR) during the study period assessed by protocol defined adjudicated relapsesRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Frexalimab, Teriflunomide, Placebo infusion, Placebo tablet, MRI contrast-enhancing agents, Cholestyramine, Activated charcoal | Multiple Sclerosis | 1,655 | 2027-05-06 | in 259 d | 2026-07-20 |
| A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic DermatitisNCT05983068Percent change from baseline in TEWL after 5 STS assessed on lesional skin.Open-label · Treatment | Phase 4 | Active, not recruiting | Drug: dupilumab | Dermatitis Atopic | 48 | 2027-04-29 | in 252 d | 2026-04-13 |
| Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® MoleculeNCT06812988Change from baseline to Week 26 in mean 2-hour mixed meal tolerance test (MMTT) stimulated C-peptide concentrationRandomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Brivekimig, Placebo | Type 1 Diabetes Mellitus | 84 | 2027-04-29 | in 252 d | 2026-03-13 |
| Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)NCT06111586Change in mean 2h mixed meal tolerance test (MMTT) stimulated C-peptide concentration, calculated from AUC from baseline to W52 for Part B (12-21 y.o.)Randomized · Triple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Frexalimab, Placebo, Insulin | Type 1 Diabetes Mellitus | 197 | 2027-04-28 | in 251 d | 2026-06-29 |
| A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical RemissionNCT07156175Proportion of participants with sustained steroid-free clinical remissionRandomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: SAR444336, Placebo | Microscopic Colitis | 54 | 2027-04-08 | in 231 d | 2026-02-24 |
| A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantNCT03319667Progression free survival (PFS)Randomized · Single-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Isatuximab SAR650984, Bortezomib, Lenalidomide, Dexamethasone | Plasma Cell Myeloma | 475 | 2027-04-05 | in 228 d | 2026-05-04 |
| Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of AgeNCT07516418Presence of any unsolicited systemic Adverse Events (AEs) reported within 30 minutes after vaccinationRandomized · Triple-masked · Prevention | Phase 1 | Recruiting | Biological: H5 Flu Investigational Medical Product (IMP) 1, H5 Flu IMP 2, H5 Flu IMP 3, RSV IMP 4, RSV IMP 5, RSV IMP 6, H5 Flu IMP 7, H5 Flu IMP 8, H5 Flu IMP 9, H5 Flu IMP 10, H5 Flu IMP 11, H5 Flu IMP 12 | Respiratory Syncytial Virus (RSV), Influenza A(H5N1) | 570 | 2027-04-04 | in 227 d | 2026-05-08 |
| Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)NCT03992417observationalBaseline Characteristics: Medical history | — | Active, not recruiting | Drug: Dupilumab SAR231893 (REGN668) | Dermatitis Atopic | 955 | 2027-03-31 | in 223 d | 2026-08-06 |
| A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe HemophiliaNCT05662319Annualized bleeding rate (ABR) in the fitusiran primary efficacy periodOpen-label · Treatment | Phase 3 | Active, not recruiting | Drug: Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC) | Hemophilia | 91 | 2027-03-25 | in 217 d | 2026-02-04 |
| Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe AsthmaNCT05097287Rate of change from week 8 to week 52 on post-BD FEV1 slope in FeNO populationRandomized · Quadruple-masked · Treatment | Phase 4 | Active, not recruiting | Drug: Dupilumab, Placebo | Asthma | 1,339 | 2027-03-16 | in 208 d | 2026-04-16 |
| An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal PolypsNCT07424144Incidence of treatment-emergent adverse events (AEs), adverse events of special interest (AESIs), serious adverse events (SAEs), AEs leading to death, and AEs leading to permanent treatment discontinuationRandomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Itepekimab (SAR440340), Placebo | Chronic Rhinosinusitis With Nasal Polyps | 59 | 2027-02-17 | in 181 d | 2026-08-12 |
| A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsNCT05584670Dose escalation part 1A, 1C and Japan Cohort F: Presence of dose-limiting toxicities (DLTs) in Cycles 1 and 2Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: SAR445877, Cetuximab, ADG126, Bevacizumab, Nivolumab, Ipilimumab | Solid Tumor | 542 | 2027-01-19 | in 152 d | 2026-06-23 |
| A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple MyelomaNCT06356571Overall response rate (ORR)Open-label · Treatment | Phase 2 | Recruiting | Drug: Isatuximab SC-OBDS, Montelukast, Dexamethasone, Acetaminophen, Diphenhydramine, Methylprednisolone, Carfilzomib | Plasma Cell Myeloma Refractory | 64 | 2027-01-08 | in 141 d | 2026-02-23 |
| Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseaseNCT07247188Number of participants reporting immediate adverse events (AEs)Randomized · Single-masked · Prevention | Phase 3 | Recruiting | Biological: PCV21, 20vPCV | Sickle Cell Disease | 100 | 2027-01-07 | in 140 d | 2026-04-15 |
| Safety of Tetanus, Diphtheria, Acellular Pertussis With 5 Acellular Pertussis Components (Tdap5) Vaccination During PregnancyNCT06258057observationalPregnancy outcome: Live birth | — | Active, not recruiting | Other: Not applicable / database analysis | Pertussis (Whooping Cough) | 365,000 | 2026-12-31 | in 133 d | 2026-04-06 |
| Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF)NCT07038473Proportion of at-risk (first-degree) relatives of T1D probands who meet the diagnostic criteria for Stage 1 or Stage 2 T1DOpen-label · Diagnostic | Not applicable | Recruiting | Procedure: Investigational Procedure | Type 1 Diabetes | 3,500 | 2026-12-25 | in 127 d | 2026-08-19 |
| A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change DiseaseNCT06500702Percent reduction in urine protein to creatinine ratio (UPCR)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: frexalimab, brivekimig, rilzabrutinib, placebo | Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion | 84 | 2026-12-23 | in 125 d | 2026-07-20 |
| A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's DiseaseNCT06958536Percentage of participants who achieve endoscopic response at Week 16Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: SAR442970, Placebo | Crohn's Disease | 99 | 2026-12-17 | in 119 d | 2026-03-27 |
| A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative ColitisNCT06975722Proportion of participants who achieve clinical remission at the end of Week 16 by modified Mayo Score (mMS)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: SAR442970, Placebo | Ulcerative Colitis | 99 | 2026-12-17 | in 119 d | 2026-04-23 |
| A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPDNCT06208306Incidence of treatment-emergent AEs, AESIs, SAEs, and AEs leading to permanent treatment discontinuationRandomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Itepekimab (SAR440340), Placebo | Chronic Obstructive Pulmonary Disease | 700 | 2026-12-01 | in 103 d | 2026-05-18 |
| Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and OlderNCT06907511Presence of immediate adverse events (AEs)Randomized · Quadruple-masked · Prevention | Phase 1/2 | Active, not recruiting | Biological: Pandemic flu H5 HA mRNA SD2 vaccine · Other: Placebo | Pandemic Influenza Immunization, Healthy Volunteers | 720 | 2026-12-01 | in 103 d | 2026-01-16 |
| Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in JapanNCT07216079AEs including SAEs and AESIsOpen-label · Treatment | Phase 3 | Active, not recruiting | Drug: rilzabrutinib | Immune Thrombocytopenia | 4 | 2026-11-30 | in 102 d | 2025-11-06 |
| Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)NCT07457580observationalParticipant demographics at teplizumab initiation | — | Recruiting | Drug: Teplizumab | Type 1 Diabetes | 60 | 2026-11-30 | in 102 d | 2026-05-27 |
| A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsNCT06834360Change from baseline in the endoscopic NPSRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS) | Chronic Rhinosinusitis With Nasal Polyps | 216 | 2026-11-06 | in 78 d | 2026-06-02 |
| A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)NCT04848779observationalProportion of participants alive and free of invasive ventilation at Week 52 of treatment | — | Active, not recruiting | Drug: Alglucosidase alfa GZ419829 | Glycogen Storage Disease Type II | 16 | 2026-10-28 | in 69 d | 2026-06-24 |
| A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsNCT06834347Change from baseline in the endoscopic NPSRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS) | Chronic Rhinosinusitis With Nasal Polyps | 231 | 2026-10-14 | in 55 d | 2026-05-20 |
| Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in SpainNCT06415175observationalDemographic characteristic of pediatric patients initiating treatment with dupilumab for Severe AD: Age | — | Active, not recruiting | Drug: Dupilumab | Atopic Dermatitis | 143 | 2026-09-30 | in 41 d | 2026-02-25 |
| Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy ParticipantsNCT07646548Pharmacokinetic (PK) parameter in serum: Cmax of dupilumabRandomized · Open-label · Basic science | Phase 1 | Active, not recruiting | Biological: Dupilumab coformulated with berahyaluronidase alfa, Dupilumab | Healthy Volunteers | 40 | 2026-09-30 | in 41 d | 2026-07-21 |
| Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical StudyNCT06033833Percentage of participants with treatment-emergent adverse eventsNon-randomized · Triple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Amlitelimab, Placebo | Asthma | 335 | 2026-09-29 | in 40 d | 2026-05-20 |
| Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male ParticipantsNCT07726914AUClastRandomized · Open-label · Treatment | Phase 1 | Not yet recruiting | Drug: Belumosudil, Belumosudil | Chronic Graft Versus Host Disease | 58 | 2026-09-28 | in 39 d | 2026-07-24 |
| Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational StudyNCT05991323observationalFrequency of reasons for dupilumab treatment initiation with the description of dosing, frequency and duration of treatment | — | Active, not recruiting | Drug: Dupilumab | Prurigo Nodularis | 100 | 2026-09-22 | in 33 d | 2025-09-16 |
| iGlarLixi CGM Study in Chinese T2D Individuals After OADsNCT06671587Superiority of mean change in the percentage of TIR [3.9-10.0 mmol/L (70-180 mg/dL)]Randomized · Open-label · Treatment | Phase 4 | Recruiting | Drug: iGlarLixi (insulin glargine/lixisenatide), Gla-100 (insulin glargine) | Type 2 Diabetes (T2D) | 678 | 2026-09-18 | in 29 d | 2026-03-17 |
| Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in TaiwanNCT06052800observationalCohort 1: change of Left ventricular mass index (LVMI) as measured by echocardiography in agalsidase beta-treated patients | — | Active, not recruiting | — | Fabry Disease | 78 | 2026-09-10 | in 21 d | 2026-05-15 |
| Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus ErythematosusNCT05039840Percentage of participants who achieved a Systemic Lupus Erythematosus Responder Index (SRI-4) response at Week 24.Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: SAR441344 IV, SAR441344 SC, Placebo IV, Placebo SC | Systemic Lupus Erythematosus | 109 | 2026-09-03 | in 14 d | 2026-08-06 |
| Validation of Chlamydia Diagnostic Codes in TriNetX US EHR DataNCT07094373observationalValidity of ICD-10-CM Diagnostic Codes for Chlamydial Infections | — | Recruiting | — | Chlamydial Infections | 533,000 | 2026-08-31 | in 11 d | 2026-07-10 |
| Teplizumab in Pediatric Stage 2 Type 1 DiabetesNCT05757713Treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), TEAEs leading to withdrawal, and serious adverse events (SAEs)Open-label · Treatment | Phase 4 | Active, not recruiting | Biological: teplizumab | Diabetes Mellitus, Type 1 | 20 | 2026-08-27 | in 7 d | 2026-01-30 |
| A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' DiseaseNCT06984627Percent change from baseline in FT4 levelsRandomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: Rilzabrutinib dose 1, Rilzabrutinib dose 2 | Graves' Disease | 30 | 2026-08-25 | in 5 d | 2026-07-07 |
| RSV Immunisation Status in Queensland (Australia)NCT07615192observationalThe proportion of immunised infants among all enrolled infants | — | Recruiting | Biological: Nirsevimab Respiratory Syncytial Virus monoclonal antibody | RSV Immunization | 1,200 | 2026-08-20 | today | 2026-07-31 |
| A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric PopulationNCT07103148Percentage of participants with seroconversion to YF virus after 1 dose of vYF compared to seroconversion after 1 dose of the Stamaril in YF-naive participants (9-24 months)Randomized · Quadruple-masked · Prevention | Phase 3 | Recruiting | Biological: Yellow fever vaccine (live), Yellow fever vaccine (live), Yellow fever vaccine (live), Measles, combinations with mumps and rubella, live attenuated | Yellow Fever Immunization | 2,440 | 2026-08-08 | — | 2026-05-06 |
| A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac DiseaseNCT06557772Change in Villus Height to Crypt Depth Ratio (Vh:Cd) from baseline to Week 28Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Amlitelimab, Placebo · Dietary supplement: SIGE, Gluten-free product (GFP) | Coeliac Disease, Celiac Disease | 229 | 2026-08-05 | — | 2026-02-25 |
| Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in FranceNCT06393946observationalPatient characteristics: Age | — | Active, not recruiting | Drug: Dupilumab | Chronic Rhinosinusitis With Nasal Polyposis | 150 | 2026-07-31 | — | 2026-06-04 |
| Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in IndiaNCT07109297Presence of immediate adverse events (AEs)Open-label · Prevention | Phase 4 | Active, not recruiting | Biological: Nirsevimab | RSV Immunization | 110 | 2026-06-30 | — | 2026-03-23 |
| A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical RoutineNCT06087627observationalPercentage (%) of participants with Investigator Global Assessment Prurigo Nodularis Stage (IGA-CPG-S) score 0 or 1 in Month 6 | — | Active, not recruiting | Drug: Dupilumab SAR231893 (REGN668) | Prurigo Nodularis | 110 | 2026-06-29actual | — | 2026-07-31 |
| A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not WorkNCT06290128Percentage of participants experiencing a responseRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Riliprubart, Placebo, Riliprubart, Placebo | Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic | 109 | 2026-06-10actual | — | 2026-08-10 |
| A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic DermatitisNCT06407934US and US reference countries: Proportion of participants who are responders AND maintained vIGA-AD ≤2 without experiencing relapse among participants who were responders at baseline of ESTUARYRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Amlitelimab, Placebo | Dermatitis Atopic | 1,541 | 2026-06-10actual | — | 2026-07-10 |
| A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)NCT06687967Proportion of participants with improvement (reduction) in weekly average of daily WI-NRS by ≥4 from baseline to Week 24Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Dupilumab, Placebo | Lichen Simplex Chronicus | 142 | 2026-06-08actual | — | 2026-07-02 |
| A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)NCT06687980Proportion of participants with improvement (reduction) in weekly average of daily WI-NRS by ≥4 from baseline to Week 24Randomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Dupilumab, Placebo | Lichen Simplex Chronicus | 138 | 2026-06-08actual | — | 2026-07-02 |
| A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry DiseaseNCT05280548Slope of left ventricular mass index as measured by cardiac magnetic resonance imaging (MRI) (central reading)Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: Venglustat (GZ402671), Agalsidase alfa, Agalsidase beta (GZ419828), Migalastat | Fabry Disease | 104 | 2026-05-22actual | — | 2026-06-24 |
| Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic EventsNCT07734753observationalComposite of Nonfatal Myocardial Infarction, Nonfatal Ischemic Stroke, or All-Cause Mortality | — | Active, not recruiting | Drug: Alirocumab, Comparator: No PCSK9i Therapy (monoclonal antibodies or small interfering RNA agents) | Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events | 4,006 | 2026-05-15actual | — | 2026-07-29 |
| A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))NCT05731128Proportion of participants achieving clinical response at Week 24Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Dupilumab, Placebo | Colitis Ulcerative | 68 | 2026-05-13actual | — | 2026-06-23 |
| Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in ChinaNCT07135986Participants 7 through 17 years of age (Cohort I): Vaccine seroresponse to meningococcal serogroups A, C, Y, and WRandomized · Quadruple-masked · Prevention | Phase 3 | Active, not recruiting | Biological: MenACYW conjugate vaccine, MenACYW135 polysaccharide vaccine, MenAC conjugate vaccine | Meningococcal Infection, Healthy Volunteers | 1,602 | 2026-05-01actual | — | 2026-05-12 |
| Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older AdultsNCT07295028Proportion of Participants With 1 or More Unsolicited Adverse Events (AEs)Randomized · Double-masked · Prevention | Phase 1 | Active, not recruiting | Biological: trivalent (RSV/hMPV/PIV3) vaccine candidate, trivalent (RSV/hMPV/PIV3) vaccine candidate, trivalent (RSV/hMPV/PIV3) vaccine candidate, bivalent (RSV/hMPV) unlicensed comparator, monovalent (RSV) unlicensed comparator, Biological/Vaccine: monovalent (hMPV) unlicensed comparator, monovalent (PIV3) unlicensed comparator · Other: Placebo | Lower Respiratory Tract Disease, Healthy Participants | 240 | 2026-04-21actual | — | 2026-05-20 |
| A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal PolypsNCT06691113Change from baseline in sinus (maxillary, ethmoid) percent opacification volume assessed by CT scanRandomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS) | Chronic Rhinosinusitis Without Nasal Polyps | 66 | 2026-03-31actual | — | 2026-05-05 |
| Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase AlfaNCT04910776Proportion of participants who are alive and free of invasive ventilation at Week 52Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: avalglucosidase alfa | Glycogen Storage Disease Type II | 17 | 2026-03-02actual | — | 2026-04-08 |
| Dose-finding Study of SAR443122 in Adult Participants With Ulcerative ColitisNCT05588843Proportion of participants who achieve clinical remission at Week 12 by modified Mayo Score (mMS)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: SAR443122, Placebo | Colitis Ulcerative | 187 | 2026-02-10actual | — | 2026-04-27 |
| A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple MyelomaNCT05704049Overall response rate (ORR) - Cohorts 1 to 3Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: Isatuximab, Carfilzomib, Dexamethasone, Dexamethasone IV, Montelukast, Acetaminophen, Diphenhydramine, Methylprednisolone | Relapsed/Refractory Multiple Myeloma | 118 | 2025-12-22actual | — | 2025-12-29 |
| A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry DiseaseNCT05206773Percent change from baseline at 6 months in the most bothersome symptom of 3 Fabry Disease Patient-Reported Outcome (FD-PRO) items (neuropathic pain in upper extremities, neuropathic pain in lower extremities, or abdominal pain)Randomized · Double-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Venglustat (GZ402671), Placebo | Fabry Disease | 122 | 2025-12-17actual | — | 2026-02-04 |
| A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)NCT06101095Change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe (EndoFLIP)Randomized · Triple-masked · Treatment | Phase 4 | Active, not recruiting | Drug: Dupilumab, Placebo | Eosinophilic Oesophagitis | 69 | 2025-11-05actual | — | 2025-12-23 |
| BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)NCT05156710Cohort A: Treatment failure rateRandomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar, Antithymocyte globulin (ATG), Tacrolimus, Mycophenolate, Corticosteroids | Transplant Rejection | 48 | 2025-10-21actual | — | 2026-02-24 |
| Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3NCT05222906Change in Scale for Assessment and Rating of Ataxia (SARA) modified total scoreRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Venglustat, imiglucerase | Gaucher's Disease Type III | 43 | 2025-10-02actual | — | 2026-07-13 |
| A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older AdultsNCT06556147Proportion of Older Adult Participants With 1 or More Unsolicited AEsRandomized · Double-masked · Prevention | Phase 1 | Active, not recruiting | Biological: VXB-241 60 mcg (Low Dose), VXB-241 120 mcg (Medium Dose), VXB-241 240 mcg (Medium-high Dose), VXB-241 480 mcg (High Dose), VXB-241 240 mcg, Arexvy 120 mcg · Other: Placebo | Healthy Volunteers | 144 | 2025-02-14actual | — | 2026-05-20 |
| SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMMNCT05405166results2025-11-14Overall Response Rate (ORR)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Isatuximab IV, Isatuximab SC, Dexamethasone, Pomalidomide, Dexamethasone, Montelukast, Paracetamol / Acetaminophen, Diphenhydramine, Methylprednisolone | Plasma Cell Myeloma Recurrent | 531 | 2024-11-06actual | — | 2025-11-14 |
| Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)NCT05002777Part A: Proportion of participants with overall hemoglobin responseOpen-label · Treatment | Phase 2 | Active, not recruiting | Drug: rilzabrutinib | Warm Autoimmune Hemolytic Anemia (wAIHA) | 22 | 2024-05-23actual | — | 2026-06-05 |
| Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple SclerosisNCT04879628results2025-09-30Mean Number of New Gadolinium (Gd)-Enhancing T1--Hyperintense (GdE T1) Lesions at Week 12 Relative to Week 8 as Measured by Brain Magnetic Resonance Imaging (MRI)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Active, not recruiting | Drug: SAR441344 IV, placebo IV, SAR441344 SC, placebo SC, MRI contrast-enhancing preparations | Multiple Sclerosis | 129 | 2022-09-21actual | — | 2025-09-30 |
| A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis BronchiectasisNCT07547436Change from baseline to Week 24 in mucus plug score (MPS) derived from chest high-resolution computerized tomography (HRCT)Randomized · Quadruple-masked · Treatment | Phase 2 | Suspendedsponsor's stated reason: The pause is for strategic business reasons to facilitate internal portfolio review. The pause is not due to any concerns with patient safety, with program benefit/risk, or with trial integrity. | Biological: SAR445399, Placebo | Non-cystic Fibrosis Bronchiectasis | 70 | 2027-10-29 | in 435 d | 2026-07-29 |
| A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsNCT07484230Change from baseline in the endoscopic NPSRandomized · Quadruple-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Sponsor decision. Not related to safety concern. | Drug: Itepekimab (SAR440340), Placebo | Chronic Rhinosinusitis With Nasal Polyps | 0 | 2027-10-20 | in 426 d | 2026-08-13 |
| A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)NCT05726682Rate of relapse free survival (RFS) post allogeneic hematopoietic stem cell transplantation (HSCT)Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Sponsor decision to cancel trial, not related to safety concern. | Drug: SAR445419 | Allogenic Stem Cell Transplantation | 0 | 2027-02-12 | in 176 d | 2024-03-05 |
| Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical PracticeNCT07615166observationalMean Percentage Reduction in Low Density Lipoprotein Cholesterol (LDL-C) From Baseline Over the 60 to 450 Days Follow-up | — | Completed | Drug: Alirocumab 150 mg, Inclisiran | Atherosclerotic Cardiovascular Disease | 996 | 2026-06-30actual | — | 2026-07-09 |
| An Observational Study to Assess Nirsevimab Immunization Rates in Eligible Infants During Their First RSV Season in the CzechiaNCT07634692observationalThe proportion of immunised infants among all enrolled infants | — | Completed | Biological: Nirsevimab Respiratory Syncytial Virus monoclonal antibody | RSV Immunization | 257 | 2026-06-26actual | — | 2026-08-10 |
| Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)NCT04550962observationalBaseline Characteristics: Socio-demographics | — | Completed | Drug: Dupilumab SAR231893 | Asthma | 376 | 2026-06-18actual | — | 2026-07-20 |
| A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes MellitusNCT06716424Percentage of participants with treatment emergent adverse events (TEAEs) including serious adverse events (SAEs)Open-label · Other | Phase 4 | Completed | Drug: iGlarLixi (insulin glargine/lixisenatide) | Type 2 Diabetes | 105 | 2026-06-12actual | — | 2026-07-10 |
| A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous UrticariaNCT07316114observationalSummary of Sociodemographic Characteristics | — | Terminatedsponsor's stated reason: Sponsor decision; the decision is not related to any safety concern. | Drug: Dupilumab | Chronic Spontaneous Urticaria | 1 | 2026-06-02actual | — | 2026-07-31 |
| A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.NCT07272629Change from baseline in the QT interval corrected using the Fridericia formula (QTcF) centrally assessed using a semi-automatic readingRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: Balinatunfib, Moxifloxacin, Placebo | Cardiac Repolarization, Healthy Volunteers | 48 | 2026-05-28actual | — | 2026-06-23 |
| A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi ArabiaNCT06714461observationalNumber of healthcare professionals who recall receiving and reading the additional risk minimization measures material for leflunomide distributed in 2022 | — | Completed | Drug: Leflunomide | Rheumatoid Arthritis, Psoriatic Arthritis | 302 | 2026-05-14actual | — | 2026-06-11 |
| A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic TherapiesNCT06616415Plasma concentrations of belumosudil at specified time pointsOpen-label · Treatment | Phase 4 | Completed | Drug: Belumosudil | Chronic Graft Versus Host Disease | 6 | 2026-05-12actual | — | 2026-05-27 |
| Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY)NCT03849716observationalBiomarker identification: Demographics | — | Completed | Other: Blood sample, Cheek swab | Dermatitis Atopic | 266 | 2026-04-20actual | — | 2026-07-06 |
| Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and OlderNCT06695117Number of participants with immediate adverse events (AEs)Randomized · Quadruple-masked · Prevention | Phase 1/2 | Completed | Biological: IIV-HD, rC19 (dose 1), IIV-HD + rC19 (dose 1), IIV-HD + rC19 (dose 2), IIV-HD + rC19 (dose 3), IIV-HD + rC19 (dose 4) · Other: Placebo (0.9% NaCl) | COVID-19 Immunization, Influenza Immunization | 980 | 2026-04-16actual | — | 2026-05-05 |
| Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic DermatitisNCT06099704observationalPercentage of participants achieving a reduction in Eczema Area and Severity Index (EASI) of at least 75% at 6 months | — | Completed | — | Moderate to Severe Atopic Dermatitis | 305 | 2026-04-14actual | — | 2026-05-15 |
| A Bioequivalence Study of Amlitelimab Delivered by 2 Different Devices in Healthy Adult ParticipantsNCT07146750PK parameter: CmaxRandomized · Open-label · Treatment | Phase 1 | Completed | Combination product: SAR445229 | Healthy Volunteers | 212 | 2026-04-08actual | — | 2026-04-20 |
| Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and OlderNCT06695130Number of participants with immediate adverse events (AEs)Randomized · Quadruple-masked · Prevention | Phase 1/2 | Completed | Biological: RIV (recombinant influenza vaccine), rC19 (dose 1), RIV + rC19 (dose 1), RIV + rC19 (dose 2), RIV + rC19 (dose 3), RIV + rC19 (dose 4) · Other: Placebo (0.9% NaCl) | COVID-19 Immunization, Influenza Immunization | 980 | 2026-04-03actual | — | 2026-05-05 |
| Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of AgeNCT07071558Presence of any unsolicited systemic adverse events (aes)Randomized · Triple-masked · Prevention | Phase 1 | Completed | Biological: RSV vaccine formulation 1 dose, RSV vaccine formulation 2 dose, RSV vaccine formulation 3 dose, RSV vaccine formulation 4 dose, RSV vaccine formulation 5 dose, RSV vaccine formulation 6 dose, RSV vaccine formulation 7 dose, RSV vaccine formulation 8 dose | Respiratory Syncytial Virus Immunization | 240 | 2026-03-17actual | — | 2026-04-28 |
| Actual Use Trial of Tadalafil 5 mgNCT06805513The proportion of inter-dosing intervals in which the recommended time between doses is followedOpen-label · Treatment | Phase 3 | Completed | Combination product: Tadalafil 5 mg tablets with a digital tool. | Erectile Dysfunction | 2,212 | 2026-03-02actual | — | 2026-07-13 |
| A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)NCT04458831observationalOverall response rate (ORR) | — | Completed | Drug: isatuximab SAR650984, Pomalidomide, Dexamethasone, Carfilzomib | Plasma Cell Myeloma | 583 | 2026-02-23actual | — | 2026-07-29 |
| Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe AsthmaNCT06102005Annualized rate of asthma exacerbation eventsRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Lunsekimig, Placebo | Asthma | 685 | 2026-02-23actual | — | 2026-03-17 |
| A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic DermatitisNCT06790121Percent change in Eczema Area and Severity Index (EASI) score from baseline to Week 24Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Lunsekimig, Placebo | Dermatitis Atopic | 150 | 2026-02-12actual | — | 2026-04-21 |
| A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal PolypsNCT06454240Change in bilateral endoscopic nasal polyp score (NPS).Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: lunsekimig, placebo | Chronic Rhinosinusitis With Nasal Polyps | 79 | 2026-01-29actual | — | 2026-04-28 |
| Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in AdultsNCT07002060Number of participants with immediate adverse eventsRandomized · Quadruple-masked · Prevention | Phase 3 | Completed | Biological: Yellow fever vaccine (live), YF vaccine (live) | Yellow Fever Immunization | 640 | 2026-01-20actual | — | 2026-02-02 |
| Safety and Immunogenicity of NVX-CoV2705NCT07079670Pseudovirus neutralization (ID50) of Omicron JN.1 subvariant vaccine expressed as GMFROpen-label · Prevention | Phase 3 | Completed | Biological: NVX-CoV2705 | COVID-19, SARS-CoV-2 Infection | 676 | 2026-01-12actual | — | 2026-06-05 |
| Real World and Epidemiology Study of Medically Attended Chlamydia Trachomatis Among Adults in GermanyNCT07002047observationalNumber of female participants with documented (confirmed) outpatient or any inpatient of pelvic inflammatory disease (PID) | — | Completed | — | Chlamydia Trachomatis | 81,239 | 2025-12-31actual | — | 2026-05-04 |
| Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3NCT03485677Assessment of pharmacokinetic (PK) parameter of eliglustat: CmaxNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Eliglustat GZ385660, Imiglucerase GZ437843 | Gaucher's Disease Type I, Gaucher's Disease Type III | 57 | 2025-12-26actual | — | 2026-06-16 |
| Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid TumorsNCT05450562Part 1A and 1B: Number of participants with Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Early discontinuation based on strategic sponsor decision not driven by any safety concerns | Biological: SAR444200, Atezolizumab | Neoplasm | 33 | 2025-12-22actual | — | 2026-01-14 |
| A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection QuestionnaireNCT06765187observationalProportion of Participants Reporting Incidence of Reactions (Local) Using Vaccinees' Perception of Injection (VAPI) Questionnaire (Age Groups [18-49 and 50-64 years]) | — | Completed | Biological: Trivalent Recombinant Influenza Vaccine | Influenza Immunization, Health Volunteers | 1,007 | 2025-12-22actual | — | 2026-04-07 |
| A First-in-human Study to Investigate Safety and Tolerability of SAR446959 in Participants With Osteoarthritis of the KneeNCT06704932Number of participants with adverse events (AEs)/treatment emergent adverse events (TEAEs) including injection site reactionsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: SAR446959, Placebo | Osteoarthritis | 32 | 2025-12-18actual | — | 2026-01-12 |
| A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.NCT06850051Presence of any unsolicited systemic Adverse Events (AEs) reported within 30 minutes after vaccinationRandomized · Quadruple-masked · Prevention | Phase 1 | Completed | Biological: TIV-HA Vaccine formulation 1 at low dose, TIV-HA formulation 1 at high dose, TIV-HA formulation 2 at low dose, TIV-HA formulation 2 at high dose, RSV/hMPV/PIV3 formulation 2 at low dose, RSV/hMPV/PIV3 formulation 1 at high dose, RSV/hMPV/PIV3 formulation 2 at high dose, RSV/hMPV/PIV3 formulation 1 at low dose, RIV4 (Supemtek®) | Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination, Parainfluenza Vaccination, Human Metapneumovirus Vaccination | 270 | 2025-12-11actual | — | 2026-01-16 |
| Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and AboveNCT05720455Number of participants with treatment-emergent adverse events (TEAEs)Open-label · Treatment | Phase 4 | Completed | Drug: Fexofenadine HCL and pseudoephedrine HCL | Rhinitis Allergic | 203 | 2025-12-05actual | — | 2026-02-17 |
| Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)NCT06665308observationalPrevalence of impaired cognitive status among adult Immune Thrombocytopenia patients | — | Completed | Other: No intervention | Chronic Immune Thrombocytopenia, Primary Immune Thrombocytopenia, Adult Immune Thrombocytopenia | 97 | 2025-11-26actual | — | 2026-01-26 |
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)NCT06181435EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Amlitelimab, Placebo | Dermatitis Atopic | 589 | 2025-11-25actual | — | 2026-08-13 |
| An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 SubstratesNCT06686628AUC and AUClast for CYP substratesOpen-label · Treatment | Phase 1 | Completed | Drug: Amlitelimab, Midazolam, Caffeine, Metoprolol, Omeprazole, Warfarin | Dermatitis Atopic | 23 | 2025-11-21actual | — | 2026-04-23 |
| Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)NCT044580516-month composite Confirmed Disability Progression (cCDP)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Tolebrutinib, Placebo | Primary Progressive Multiple Sclerosis | 767 | 2025-11-14actual | — | 2026-01-07 |
| Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic DermatitisNCT06058156Percent change from baseline in EASIRandomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision. Not related to safety concern. | Drug: SAR444656 (KT-474), Placebo | Atopic Dermatitis | 70 | 2025-10-23actual | — | 2025-12-11 |
| A Study to Evaluate the Quality of Life in Male and Female Adult Participants With Severe Asthma Treated With Dupilumab in a Real-world SettingNCT06018441observationalChange from baseline in health-related quality of life (HRQoL), as measured by the St. George's Respiratory Questionnaire (SGRQ) | — | Completed | — | Asthma | 112 | 2025-10-10actual | — | 2025-12-09 |
| A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaNCT06028230Percent change from baseline in total abscess and inflammatory nodule (AN) countRandomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision. Not related to safety concern. | Drug: SAR444656 (KT-474), Placebo | Hidradenitis Suppurativa | 70 | 2025-10-09actual | — | 2025-12-11 |
| A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With PlaceboNCT06015308Percentage of participants with a positive tetanus response at Week 16Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Amlitelimab, Placebo · Biological: Tdap vaccine, PPS vaccine | Dermatitis Atopic | 224 | 2025-10-01actual | — | 2026-08-10 |
| Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)NCT07615179observationalComposite of nonfatal myocardial infarction, nonfatal ischemic stroke, or all-cause mortality | — | Completed | Drug: Alirocumab, Comparator: No PCSK9i Therapy (either mAb or siRNA) | Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events | 4,545 | 2025-09-30actual | — | 2026-06-15 |
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia AreataNCT06444451Change from baseline in Severity of Alopecia Tool (SALT) score at Week 36Randomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision; the decision is not related to any safety concern | Drug: Amlitelimab, Placebo | Alopecia Areata | 166 | 2025-09-24actual | — | 2026-08-10 |
| A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi ArabiaNCT06714448observationalPercentage of healthcare professionals who received and read the educational materials | — | Completed | Drug: Sodium valporate | Epilepsy, Seizures | 455 | 2025-09-22actual | — | 2026-04-28 |
| Goal Attainment and Physical Activity in People With Hemophilia ANCT06530030observationalProportion of total goals achieved | — | Terminatedsponsor's stated reason: Early discontinuation based on sponsor decision not driven by any safety concerns. | Drug: efanesoctocog alfa | Hemophilia A | 3 | 2025-09-18actual | — | 2026-01-20 |
| A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis BronchiectasisNCT06280391Annualized rate of moderate or severe Pulmonary exacerbations (PEs) over the treatment periodRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Itepekimab (SAR440340), Placebo | Bronchiectasis | 312 | 2025-09-16actual | — | 2026-02-12 |
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical CorticosteroidsNCT06224348EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors | Dermatitis Atopic | 643 | 2025-08-21actual | — | 2026-08-13 |
| A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological MalignanciesNCT06508489Number of participants with adverse events (AEs)/serious adverse events (SAEs)/adverse events of special interest (AESIs), laboratory abnormalitiesOpen-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Early discontinuation based on strategic sponsor decision not driven by any safety concerns | Biological: SAR443579 · Drug: venetoclax, azacitidine | Acute Myeloid Leukemia | 7 | 2025-08-08actual | — | 2025-08-22 |
| Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD EmphysemaNCT05856331Serum functional AAT (fAAT) levels at steady-stateRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: SAR447537, Zemaira | Alpha 1-Antitrypsin Deficiency, Emphysema | 99 | 2025-08-06actual | — | 2025-08-11 |
| Description of Patients With Type 1 Diabetes Treated With TeplizumabNCT06892002observationalParticipant demographic characteristics at teplizumab initiation | — | Completed | Drug: Teplizumab | Type 1 Diabetes | 110 | 2025-08-05actual | — | 2025-08-15 |
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic DermatitisNCT06130566EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Amlitelimab, Placebo | Dermatitis Atopic | 601 | 2025-07-23actual | — | 2026-07-22 |
| Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid TumorsNCT04717375Part 1: Incidence of treatment-emergent adverse events (TEAEs) dose limiting toxicities (DLT)Non-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Early discontinuation based on strategic sponsor decision not driven by any safety concerns | Drug: SAR444881, Pembrolizumab, Cetuximab, Carboplatin, Pemetrexed | Cancer, Neoplasm | 125 | 2025-07-02actual | — | 2025-08-07 |
| A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid ArthritisNCT06073093Proportion of participants achieving at least 20% improvement from baseline in the American College of Rheumatology (ACR) score at week 12Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: SAR441566, Placebo | Rheumatoid Arthritis | 264 | 2025-06-18actual | — | 2025-07-11 |
| A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech RepublicNCT05527964observationalThe regression coefficient for at least 75% reduction in the Eczema Area and Severity Index score (EASI75) at week 24 adjusted to baseline characteristics predicting the change in EQ-5D utility | — | Completed | — | Atopic Dermatitis | 146 | 2025-06-16actual | — | 2025-08-15 |
| First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)NCT05086315results2026-07-06Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Drug: SAR443579 | Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia | 101 | 2025-06-13actual | — | 2026-07-06 |
| Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on DialysisNCT02859896results2026-07-02Percentage of Participants Who Achieved 2 Consecutive >=30% Reductions in Intact Parathyroid Hormone From Baseline up to Week 12Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: The study was conducted to fulfill a post-marketing commitment (PMC).FDA acknowledged the fulfillment of this PMC. | Drug: Doxercalciferol (GZ427397), Calcitriol | Secondary Hyperparathyroidism-Chronic Kidney Disease | 21 | 2025-06-11actual | — | 2026-07-02 |
| A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)NCT05839626Dose escalation (part 1a - RRMM) Presence of dose limiting toxicities (DLT)Randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Early discontinuation based on sponsor decision not driven by any safety concerns; phase 2 was not initiated. | Drug: SAR445514 | Relapsed/Refractory Multiple Myeloma, Amyloid Light-chain Amyloidosis | 32 | 2025-05-26actual | — | 2026-05-27 |
| Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)NCT04751487Annualized rate of moderate or severe acute exacerbation of COPD (AECOPD) in former smokersRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Itepekimab SAR440340, Placebo | Chronic Obstructive Pulmonary Disease | 1,239 | 2025-04-21actual | — | 2026-04-15 |
| Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)NCT04701983Annualized rate of moderate or severe acute exacerbation of COPD (AECOPD)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Itepekimab SAR440340, Placebo | Chronic Obstructive Pulmonary Disease | 1,127 | 2025-04-11actual | — | 2026-04-15 |
| A Study to Evaluate Safety and Tolerability of Olipudase Alfa in Pediatric and Adult Participants With Acid Sphingomyelinase Deficiency (ASMD) Who Completed the DFI12712 or the LTS13632 Study in FranceNCT06949358results2026-04-13Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Olipudase alfa | Acid Sphingomyelinase Deficiency | 3 | 2025-04-08actual | — | 2026-04-13 |
| Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)NCT03560466results2025-11-21Main Study: Number of Participants With Any Treatment-Emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab (SAR231893/REGN668), Asthma controller therapies (incl. prednisone/prednisolone), Asthma reliever therapies | Asthma | 378 | 2025-04-01actual | — | 2025-11-21 |
| Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPDNCT05326412Change from baseline in itepekimab pharmacodynamic normalized enrichment score (NES) derived from former smokers in endobronchial biopsies in current smokers with COPDOpen-label · Treatment | Phase 2 | Completed | Drug: Itepekimab SAR440340 | Chronic Obstructive Pulmonary Disease | 49 | 2025-03-05actual | — | 2026-03-11 |
| Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With AchondroplasiaNCT06067425results2026-06-25Stage 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision. Not related to safety concern. | Drug: SAR442501 | Osteochondrodysplasia | 16 | 2025-02-12actual | — | 2026-06-25 |
| Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis SuppurativaNCT06118099The clinical response as measured by the percentage of participants achieving HiSCR50 at Week 16Randomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision; the decision is not related to any safety concern | Drug: Amlitelimab, Placebo | Hidradenitis | 90 | 2025-02-06actual | — | 2026-02-04 |
| Data Analysis of Adult and Pediatric Participants With Acid Sphingomyelinase Deficiency (ASMD) on Early Access to Olipudase Alfa in FranceNCT05359276observationalChange in pulmonary function diffusion capacity of lung for carbon monoxide (DLco) | — | Completed | Drug: Olipudase alfa | Acid Sphingomyelinase Deficiency (ASMD) | 40 | 2024-12-31actual | — | 2025-02-06 |
| Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic PurpuraNCT05468320results2025-12-30Percentage of Participants Who Achieved Remission Without Requirement of Therapeutic Plasma Exchange During Overall Study PeriodOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Caplacizumab, Corticosteroids · Biological: anti-CD20 antibody | Thrombotic Thrombocytopenic Purpura | 51 | 2024-12-26actual | — | 2025-12-30 |
| Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI)NCT04684524results2025-12-22Change From Baseline to Week 52 in Opacification of Sinuses Assessed by CT Scan Using the LMK ScoreRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab SAR231893, Placebo | Allergic Fungal Rhinosinusitis | 62 | 2024-12-14actual | — | 2025-12-22 |
| An Observational Study on Sarilumab-exposed PregnanciesNCT03378219observationalRate of major structural birth defect | — | Completed | Drug: Sarilumab SAR153191 (REGN88) | Rheumatoid Arthritis -Exposure During Pregnancy | 113 | 2024-12-06actual | — | 2025-01-17 |
| Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple SclerosisNCT03996291results2025-10-23Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Tolebrutinib | Relapsing Multiple Sclerosis | 125 | 2024-11-26actual | — | 2025-10-23 |
| A Non-Interventional National Study in Pediatric Patients With Unexplained Enlarged SpleenNCT04845958observationalPercentage of patients diagnosed with GD among enrolled patients | — | Completed | — | Gaucher Disease, Splenomegaly, Acid SphingoMyelinase Deficiency | 60 | 2024-11-25actual | — | 2025-09-23 |
| A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple SclerosisNCT05630547results2025-10-15Part A: Change From Baseline to Week 48 in Serum Neurofilament Light Chain (sNfL) LevelsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The study was terminated as it did not meet its primary and key secondary endpoints | Drug: SAR443820 · Other: Placebo | Multiple Sclerosis | 174 | 2024-11-21actual | — | 2025-10-15 |
| A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque PsoriasisNCT06073119results2025-11-10Percentage of Participants With a 75% or Greater Psoriasis Area and Severity Index (PASI) Score Reduction From Baseline (PASI75) at Week 12Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: SAR441566, Placebo | Psoriasis | 221 | 2024-11-13actual | — | 2025-11-10 |
| Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)NCT05231668Number of participants with adverse events (AEs)/treatment-emergent adverse events (TEAEs)Randomized · Triple-masked · Treatment | Phase 1 | Terminated | Drug: SAR439459, Placebo | Osteogenesis Imperfecta | 16 | 2024-11-12actual | — | 2025-09-11 |
| A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)NCT05526521results2025-11-19Serum Concentration of Dupilumab at Weeks 12 and 24Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab | Chronic Spontaneous Urticaria | 15 | 2024-11-11actual | — | 2025-11-25 |
| Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast CancerNCT03284957results2025-11-24Parts A, C, F, H, J: Number of Participants With Study Treatment-Related Dose-Limiting Toxicities (DLTs)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor decision to prematurely stop the study, not linked to any safety concern. | Drug: Amcenestrant, Palbociclib, Alpelisib, Everolimus, Abemaciclib | Breast Cancer | 136 | 2024-11-08actual | — | 2025-11-24 |
| A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of FabrazymeNCT06019728results2025-10-21Percent Reduction in Shortest Tolerated Infusion Duration From Pre-study Average of Recent 3 InfusionsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: AGALSIDASE BETA (GZ419828), Acetaminophen, Diphenhydramine, Dexamethasone, Montelukast, Loratadine, Cetirizine, Fexofenadine | Fabry's Disease | 8 | 2024-10-25actual | — | 2025-10-21 |
| EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 PatientsNCT04998604results2025-10-23Change From Baseline to Week 24 in Nasal Polyp ScoreRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Dupilumab, Omalizumab, Placebo | Chronic Rhinosinusitis With Nasal Polyps, Asthma | 360 | 2024-10-16actual | — | 2025-10-23 |
| An Observational, Retrospective Multicentre Medical Record Review to Describe the Post-authorisation Early Clinical Experience of Dupilumab in the Treatment of Adult Severe AsthmaNCT06064526observationalOral corticosteroid (OCS) dose | — | Completed | Other: No intervention | Asthma | 144 | 2024-10-15actual | — | 2024-11-14 |
| Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe AsthmaNCT05421598results2026-03-30Annualized Rate of Severe Asthma Exacerbation Events Over 48 WeeksRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Amlitelimab, Placebo | Asthma | 437 | 2024-10-11actual | — | 2026-03-30 |
| Dupilumab in Chinese Adult Participants With CRSwNPNCT05878093results2025-09-25Change From Baseline in Nasal Polyps Score at Week 24Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab, Placebo, Budesonide | Chronic Rhinosinusitis With Nasal Polyps | 63 | 2024-09-06actual | — | 2025-09-25 |
| Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)NCT04411641results2025-06-18Time to Onset of 6-Month Confirmed Disability Progression (CDP) as Assessed by Expanded Disability Status Scale (EDSS)Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Tolebrutinib, Placebo to match Tolebrutinib | Non-relapsing Secondary Progressive Multiple Sclerosis | 1,131 | 2024-08-29actual | — | 2025-07-02 |
| Implementation and Evaluation of a Rare Disease Algorithm to Identify Persons at Risk of Gaucher Disease Using Data From Electronic Health Records (EHRs) in the United States (Project Searchlight)NCT05908656The proportion of persons with GD (including those with GD identified in Phase II and those previously undiagnosed who subsequently test positive for GD in Phase III) out of all persons highly ranked by the RDAOpen-label · Screening | Not applicable | Completed | Procedure: Investigational procedure | Gaucher Disease | 13 | 2024-08-26actual | — | 2024-11-19 |
| A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis SuppurativaNCT05849922results2026-01-29Period A (DB Period): Percentage of Biologic and Small Molecule Immunosuppressive-Naïve Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: SAR442970, Placebo | Hidradenitis Suppurativa | 86 | 2024-08-22actual | — | 2026-01-29 |
| Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)NCT04180488results2025-08-20Change From Baseline in Weekly Itch Severity Score at Week 24Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab SAR231893, Placebo, non sedating H1-antihistamine | Chronic Spontaneous Urticaria | 397 | 2024-08-01actual | — | 2025-08-20 |
| Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)NCT04410991results2025-06-18Annualized Relapse Rate (ARR) as Assessed by Confirmed Protocol-defined Adjudicated RelapsesRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Tolebrutinib, Teriflunomide HMR1726, Placebo to match Tolebrutinib, Placebo to match Teriflunomide | Relapsing Multiple Sclerosis | 899 | 2024-07-16actual | — | 2025-07-02 |
| Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)NCT04410978results2025-06-18Annualized Relapse Rate (ARR) as Assessed by Confirmed Protocol-defined Adjudicated RelapsesRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Tolebrutinib, Teriflunomide, Placebo to match Tolebrutinib, Placebo to match Teriflunomide | Relapsing Multiple Sclerosis | 974 | 2024-07-15actual | — | 2025-07-02 |
| A Randomized Controlled Trial to Compare the Glycemic Control, With or Without the Connected Solution, of Adult Type 2 Diabetic Participants on Basal Insulin in TaiwanNCT05684341Change from baseline in HbA1c at Week 24Randomized · Open-label · Treatment | Not applicable | Completed | Combination product: Connected Solution with H2S app which connects with blood glucose meter (BGM) | Type 2 Diabetes Mellitus | 200 | 2024-06-18actual | — | 2026-07-21 |
| A Study in Male and Female Adult Participants With Chronic Rhinosinusitis With Nasal Polyps In the Greater Gulf RegionNCT05649813observationalPercentage of participants with mild, moderate or severe disease (measured by visual analogue scale [VAS] score) | — | Completed | — | Chronic Rhinosinusitis With Nasal Polyps | 148 | 2024-06-14actual | — | 2024-07-11 |
| A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy ParticipantsNCT06342700Relative bioavailability as assessed by rilzabrutinib Cmax following administration of the test and reference formulations in the fasted stateRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Rilzabrutinib crystalline form, Rilzabrutinib amorphous form | Autoimmune Disorder, Healthy Volunteers | 28 | 2024-04-23actual | — | 2025-09-03 |
| Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced MalignanciesNCT04418661results2025-04-20Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor's decision not related to any safety concern | Drug: Vociprotafib, Pembrolizumab, Adagrasib | Metastatic Neoplasm | 65 | 2024-04-04actual | — | 2025-05-29 |
| Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)NCT04045795Assessment of adverse events (AEs)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: isatuximab SAR650984 IV, pomalidomide, dexamethasone, isatuximab SAR650984 SC · Device: Investigational injector device | Multiple Myeloma | 56 | 2024-03-27actual | — | 2025-09-12 |
| A Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatment With Dupilumab Injection (Dupixent®)NCT05070663observationalMedical history (including history of asthma) | — | Completed | — | Asthma | 105 | 2024-03-14actual | — | 2026-06-05 |
| Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLCNCT04524689results2025-03-17All Cohorts: Number of Participants With Study Drug-Related Dose-Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision, the decision is not related to any safety concern. | Drug: SAR408701 (Tusamitamab ravtansine), Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed | Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) | 57 | 2024-03-12actual | — | 2025-10-29 |
| Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)NCT05237284results2025-03-21Part A: Change From Baseline to Week 24 in the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) Total ScoreRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The study was terminated as its Part A did not meet the primary endpoint. | Drug: SAR443820, Placebo | Amyotrophic Lateral Sclerosis | 305 | 2024-03-07actual | — | 2025-03-21 |
| Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEANCT05245071results2025-03-25Objective Response Rate (ORR)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision, the decision is not related to any safety concern. | Drug: Tusamitamab ravtansine | Non-squamous Non-small Cell Lung Cancer | 22 | 2024-03-06actual | — | 2025-08-29 |
| First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHLNCT04401020Determine maximum tolerated dose (MTD)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision based on limited clinical benefit observed in both Multiple Myeloma and Non-Hodgkin Lymphoma cohorts | Drug: SAR442257 | Neoplasm Malignant | 47 | 2024-03-02actual | — | 2026-08-14 |
| Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 InflammationNCT04456673results2025-03-17Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-week Treatment PeriodRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo | Chronic Obstructive Pulmonary Disease | 935 | 2024-02-28actual | — | 2025-05-29 |
| A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid LeukemiaNCT05712278Incidence of dose-limiting (DLT) toxicityOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor's decision | Drug: SAR445419, fludarabine, cytarabine | Acute Myeloid Leukaemia | 7 | 2024-02-23actual | — | 2026-06-05 |
| Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid TumorsNCT04659603results2025-03-25Objective Response Rate (ORR)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision, the decision is not related to any safety concern. | Drug: tusamitamab ravtansine, Gemcitabine | Breast Cancer Metastatic, Pancreatic Carcinoma Metastatic | 50 | 2024-02-16actual | — | 2025-10-01 |
| Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe AsthmaNCT05104892Proportion of participants with an LOAC event during the treatment periodRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Rilzabrutinib, placebo | Asthma | 196 | 2024-02-06actual | — | 2024-03-07 |
| A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care SettingNCT05073783observationalNumber of participants with treatment-emergent adverse events (TEAEs) | — | Completed | — | Pompe Disease, Mucopolysaccharidosis Type I (MPS I) | 57 | 2024-01-31actual | — | 2024-02-14 |
| A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic FunctionNCT05718258Maximum venglustat plasma concentration observed (Cmax)Open-label · Treatment | Phase 1 | Completed | Drug: Venglustat (GZ402671) | Hepatic Function Abnormal | 26 | 2024-01-29actual | — | 2025-09-15 |
| Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in ChinaNCT05624112Percent change from baseline in TEWL after 5 skin tape stripping (STS) assessed on lesional skin at Week16 in AD patients.Non-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Dupilumab | Atopic Dermatitis, Dermatitis Atopic | 44 | 2024-01-25actual | — | 2025-09-15 |
| Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid TumorsNCT05013554Part 1: Dose Escalation Determine the MTD/maximum administered dose (MAD) and RD(s) of SAR443216Non-randomized · Open-label · Treatment | Phase 1 | Terminated | Drug: SAR443216 IV, SAR443216 SC | Neoplasm Malignant, Breast Cancer, Lung Neoplasm Malignant, Gastric Cancer, Neoplasm | 44 | 2024-01-15actual | — | 2025-09-15 |
| A Study of an Existing Database to Assess the Treatment Persistence to Basal Insulin in Type 2 Diabetes Mellitus Patients in a Structured Patient Education Program in IndiaNCT05628090observationalProportion of patients persisting on insulin glargine (Lantus® or Toujeo®) at the end of 6th month | — | Completed | — | Type 2 Diabetes Mellitus (T2DM) | 47,885 | 2023-12-29actual | — | 2024-03-08 |
| Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in ChinaNCT05680298Percent change from baseline in TEWL after 5 STS assessed on lesional skin at Week 16 in AD patients.Non-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Dupilumab | Atopic Dermatitis | 34 | 2023-12-22actual | — | 2025-02-10 |
| A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical IllnessNCT05819112observationalChange in the incidence of VTE, from index date to Day 90 | — | Terminatedsponsor's stated reason: Sponsor's decision. Termination decision unrelated to safety profile. | — | Venous Thromboembolism | 14,799 | 2023-12-15actual | — | 2024-10-30 |
| Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With EnoxaparinNCT05819125observationalChange in the incidence of symptomatic VTE, from index date to Day 90 | — | Terminatedsponsor's stated reason: Sponsor's decision. Termination decision unrelated to safety profile. | — | Venous Thromboembolism | 21,000 | 2023-12-15actual | — | 2024-10-29 |
| Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24NCT06059456observationalVaccinee reporting rate of suspected adverse drug reactions (ADRs) following routine vaccination with VaxigripTetra® and Efluelda® | — | Completed | Biological: Quadrivalent Influenza Vaccine, High-Dose Quadrivalent Influenza Vaccine | Influenza Immunization (Healthy Volunteers) | 2,078 | 2023-12-15actual | — | 2025-03-24 |
| Study Based on Electronic Health RecOrds to Identify Patients at High-risk of Fabry DiseasE (HOPE Fabry)NCT05671770observationalNumber and proportion of patients at high-risk for FD in the CCAD EMR database | — | Completed | — | Fabry Disease | 15 | 2023-12-14actual | — | 2024-03-06 |
| Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single and Repeated Doses of SAR444336 in Healthy Adult ParticipantsNCT05876767Part 1: Number of subjects with treatment-emergent adverse events (TEAEs)Randomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: SAR444336, Placebo | Healthy Volunteer | 76 | 2023-12-12actual | — | 2025-09-16 |
| A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 DiabetesNCT05607160observationalProportion of participants achieving the HbA1c target value | — | Completed | — | Type 2 Diabetes Mellitus (T2DM) | 82 | 2023-12-11actual | — | 2024-04-12 |
| To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry DiseaseNCT04143958Change in Plasma globotriaosylsphingosine (lyso-GL3) levelRandomized · Open-label · Treatment | Phase 4 | Withdrawnsponsor's stated reason: The Sponsor terminated the study due to recruitment infeasibility without having enrolled any patient. | Drug: agalsidase beta (GZ419828), agalsidase alfa | Fabry Disease | 0 | Nov 2023 | — | 2023-04-07 |
| Dupilumab in CRSsNPNCT04678856results2024-12-18Change From Baseline to Week 24 in Opacification of Sinuses Assessed by Computed Tomography (CT) Scan Using the Lund Mackay (LMK) Score in Dupilumab GroupRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Dupilumab SAR231893, Placebo | Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis, Chronic Sinusitis, Sinus Disorder, Respiratory Disorder | 71 | 2023-11-14actual | — | 2026-07-30 |
| Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)NCT04572841results2025-10-09Change From Baseline to Week 12 in ESSDAI ScoreRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: SAR441344, Placebo | Sjögren's Syndrome, Sjogren's Syndrome | 84 | 2023-11-08actual | — | 2025-10-09 |
| iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)NCT05413369results2024-10-30Change in HbA1c From Baseline to Week 24: Non-Inferiority AnalysisRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Insulin glargine/Lixisenatide, IDegAsp, Metformin, SGLT2 inhibitor | Type 2 Diabetes Mellitus | 582 | 2023-10-20actual | — | 2025-09-24 |
| A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566NCT05844735Treatment part I: Photosensitivity Index (PI) at 10 minutes post UV irradiation under Condition 1Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: SAR441566, Placebo, Ciprofloxacin | Rheumatoid Arthritis | 60 | 2023-10-15actual | — | 2025-09-16 |
| Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type ⅢNCT04656600Changes in haemoglobinOpen-label · Treatment | Phase 4 | Completed | Drug: Cerezyme® / Imiglucerase | Gaucher's Disease | 12 | 2023-10-12actual | — | 2025-09-15 |
| A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent AsthmaNCT04502862results2024-11-26Change From Baseline to Week 12 in Sleep Disturbance Score Using the Asthma Sleep Disturbance Questionnaire (ASDQ)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: SAR231893, Placebo | Asthma | 202 | 2023-10-03actual | — | 2024-12-06 |
| SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer PatientsNCT04154956results2024-11-01Progression-free Survival (PFS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Sponsor decision, the decision is not related to any safety concern. | Drug: SAR408701, Docetaxel | Non-small Cell Lung Cancer Metastatic | 389 | 2023-09-22actual | — | 2026-05-18 |
| A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]NCT05179603results2025-10-02Complete Response Rate (CRR)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Early discontinuation based on strategic sponsor decision not driven by any safety concerns | Drug: THOR-707, Pembrolizumab | Classic Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma | 14 | 2023-09-14actual | — | 2025-12-24 |
| A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)NCT04913220results2026-02-04All Cohorts: Objective Response Rate (ORR)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Early discontinuation based on strategic sponsor decision not driven by any safety concerns | Drug: THOR-707, Cemiplimab | Malignant Melanoma, Squamous Cell Carcinoma of Skin | 46 | 2023-08-22actual | — | 2026-02-04 |
| Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid TumorsNCT05429762Change from baseline in QT-interval corrected (QTcF) centrally assessedOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Tusamitamab ravtansine clinical development program is discontinued as CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival. The decision is not related to any safety concern. | Drug: Tusamitamab ravtansine | Neoplasm | 56 | 2023-08-01actual | — | 2025-04-06 |
| Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal ImpairmentNCT05552859results2024-09-05Difference in the Mean Change From Baseline to Week 24 in HbA1c Level (Gla-300 vs IDeg-100)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Terminatedsponsor's stated reason: Sponsor decision to cancel trial due to poor recruitment/ severe recruitment delay and not related to safety concern. | Drug: Insulin glargine 300 U/mL, Insulin degludec 100 U/mL | Type 2 Diabetes Mellitus, Renal Impairment | 62 | 2023-07-28actual | — | 2025-09-08 |
| A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)NCT05104567results2025-07-01Cohort A: Objective Response Rate (ORR)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: THOR-707, Pembrolizumab, Cetuximab | Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Oesophageal Adenocarcinoma | 138 | 2023-07-26actual | — | 2025-09-24 |
| A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)NCT05061420results2025-09-22Cohort A1: Objective Response Rate (ORR)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Drug: Pembrolizumab, SAR444245 (Thor-707), Cetuximab | Squamous Cell Carcinoma of Head and Neck | 59 | 2023-07-21actual | — | 2025-09-22 |
| Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 AntihistamineNCT05107115results2026-08-06Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: rilzabrutinib, placebo | Chronic Spontaneous Urticaria | 160 | 2023-07-19actual | — | 2026-08-06 |
| A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)NCT04914897results2025-10-02Cohorts A1 and A2: Objective Response Rate (ORR)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Drug: THOR-707, Pembrolizumab | Pleural Mesothelioma, Non-small Cell Lung Cancer | 106 | 2023-07-18actual | — | 2025-10-02 |
| A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants.NCT05858788Assessment of plasma pharmacokinetic (PK) parameters for SAR441566: CmaxOpen-label · Treatment | Phase 1 | Completed | Drug: SAR441566 | Rheumatoid Arthritis | 10 | 2023-07-17actual | — | 2025-09-18 |
| A Study in Male and Female Adult Patients With Atopic Dermatitis Treated With Dupilumab in TaiwanNCT05442645observationalCharacterization of the use patterns of phototherapy and immunosuppressants prior to dupilumab treatment: Used regimens | — | Completed | — | Atopic Dermatitis | 80 | 2023-06-27actual | — | 2024-07-18 |
| The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe AsthmaNCT04400318results2024-07-10Percentage of Participants Who Achieved Fractional Exhaled Nitric Oxide (FeNO) Less Than (<) 25 Parts Per Billion (Ppb) at Week 24Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Dupilumab, Placebo | Asthma | 109 | 2023-06-26actual | — | 2025-09-09 |
| Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)NCT04661033results2024-08-27Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) And Treatment Emergent Serious Adverse Events (TESAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Study discontinuation based on strategic sponsor decision; not driven by any safety concerns. | Drug: Isatuximab SAR650984 | Warm Autoimmune Hemolytic Anemia (wAIHA) | 8 | 2023-06-26actual | — | 2024-12-05 |
| Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic DermatitisNCT05018806results2026-07-13Percent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) ScoreRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Placebo, Rilzabrutinib | Atopic Dermatitis | 124 | 2023-06-23actual | — | 2026-07-13 |
| Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric CancerNCT05071053results2024-12-05Part 1: Number of Participants With Study-Drug Related Dose Limiting Toxicities (DLTs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision, the decision is not related to any safety concern. | Drug: Ramucirumab (CYRAMZA®), Tusamitamab ravtansine (SAR408701) | Adenocarcinoma Gastric, Gastrooesophageal Cancer | 35 | 2023-06-23actual | — | 2025-08-22 |
| SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM PatientsNCT01749969Number of patients with adverse events when treated with SAR650984 (isatuximab) in combination with LDOpen-label · Treatment | Phase 1 | Completed | Drug: isatuximab SAR650984, lenalidomide, dexamethasone | Plasma Cell Myeloma | 57 | 2023-06-20actual | — | 2023-07-13 |
| An Observational Study on Teriflunomide-exposed PregnanciesNCT03198351observationalRate of major structural defects in live born infants | — | Completed | Drug: Teriflunomide (HMR1726) | Multiple Sclerosis | 220 | 2023-06-13actual | — | 2023-08-28 |
| Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus ErythematosusNCT04781816results2024-06-24Percent Change From Baseline in Cutaneous Erythematosus Disease Area and Severity Index - Activity (CLASI-A) Sub-Score at Week 12Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: SAR443122, Placebo | Cutaneous Lupus Erythematosus | 78 | 2023-05-25actual | — | 2025-08-27 |
| A PK Comparability Study of Two Different Amlitelimab Drug Products in Healthy ParticipantsNCT05796479Part 1: Maximum Plasma concentration observed (Cmax )Randomized · Open-label · Other | Phase 1 | Completed | Drug: Amlitelimab DP1, Amlitelimab DP2 | Healthy Volunteers | 32 | 2023-05-22actual | — | 2025-09-19 |
| A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD)NCT04106544Time of first occurrence and recurrence of the clinical features and medical interventions related to chronic ASMDOpen-label · Other | Not applicable | Completed | Procedure: Investigational Procedures | Sphingomyelin Lipidosis | 84 | 2023-05-15actual | — | 2023-08-16 |
| A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy AdultsNCT06326814Number of participants with adverse events (AEs)/treatment-emergent adverse events (TEAEs)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: Humanized anti-Factor Bb monoclonal antibody, Placebo | Paroxysmal Nocturnal Hemoglobinuria | 54 | 2023-05-05actual | — | 2024-03-22 |
| A Pharmacokinetic and Tolerability Study of Fexinidazole in a Single Oral Dose in Adult Participants With Mild and Moderate Hepatic ImpairmentNCT05607173Cmax for fexinidazole and metabolites M1, M2Non-randomized · Open-label · Other | Phase 1 | Completed | Drug: Fexinidazole (HOE239) | Hepatic Function Abnormal | 21 | 2023-05-03actual | — | 2025-09-19 |
| Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) PatientsNCT03194867results2024-06-14Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Isatuximab SAR650984, Cemiplimab REGN2810 | Plasma Cell Myeloma | 109 | 2023-04-05actual | — | 2024-06-14 |
| Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes MellitusNCT05114590results2024-05-24Change From Baseline to Week 16 in the Percentage of Time in Range [70 to 180 Milligram Per Deciliter (mg/dL)]Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Insulin glargine/Lixisenatide | Type 2 Diabetes Mellitus | 124 | 2023-03-28actual | — | 2025-09-09 |
| A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants of Atleast 12 Years Old Receiving Dupilumab Injections in Gulf CountriesNCT05214326observationalPercentage of patients achieving an Atopic Dermatitis Control Tool (ADCT) score less than 7 (defined as in control according to ADCT) | — | Completed | — | Dermatitis Atopic | 187 | 2023-03-21actual | — | 2023-11-29 |
| Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)NCT04394624results2024-03-28Doublet Cohort - Part 1: Number of Participants With Study Drug-Related Dose-Limiting Toxicity (DLT)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision, the decision is not related to any safety concern. | Drug: SAR408701, ramucirumab, pembrolizumab | Non-small Cell Lung Cancer Metastatic | 31 | 2023-03-06actual | — | 2025-06-06 |
| A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension PeriodNCT05002933Mean change in HbA1c from baseline to week 24Open-label · Treatment | Phase 4 | Completed | Drug: Insulin glargine 300 U/ml | Type 2 Diabetes Mellitus | 570 | 2023-02-24actual | — | 2025-09-22 |
| First-in-human Study of SAR443765 in Healthy Participants and in Asthmatic ParticipantsNCT05366764Number of participants with adverse events (AEs) /TEAEsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: SAR443765, Placebo, Salbutamol or levosalbutamol | Asthma | 36 | 2023-02-24actual | — | 2025-09-10 |
| Efficacy and Safety of Tolebrutinib (SAR442168) Tablets in Adult Participants With Generalized Myasthenia GravisNCT05132569results2024-04-08DB Period: Change From Baseline in Myasthenia Gravis-activities of Daily Living (MG-ADL) Total Score at Week 26Randomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: For strategic reasons the Tolebrutinib MG study has been terminated | Drug: Tolebrutininb, Placebo | Myasthenia Gravis | 6 | 2023-02-21actual | — | 2025-09-09 |
| Study to Compare the Efficacy of Pristinamycin (Pyostacine ®) Versus Amoxicillin in the Treatment of Acute Community Acquired PneumoniaNCT02332577Percentage of patients cured established from the clinical course and pulmonary radiological courseRandomized · Double-masked · Treatment | Phase 4 | Terminatedsponsor's stated reason: The sponsor stopped the study due to low recruitment with no safety concerns | Drug: PRISTINAMYCIN XRP7263, Amoxicillin, Amoxicillin Placebo, PRISTINAMYCIN Placebo | Pneumonia | 161 | 2023-02-20actual | — | 2023-05-08 |
| Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injectorNCT05129241observationalAbsolute change from baseline to week 12 in low-density lipoprotein cholesterol (LDL-C) | — | Completed | — | Primary Hypercholesterolaemia and Mixed Dyslipidaemia, Atherosclerotic Cardiovascular Disease | 163 | 2023-02-16actual | — | 2025-03-24 |
| A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate PsoriasisNCT05453942Number of participants with treatment-emergent adverse events (TEAE) including SAE and AESIRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: SAR441566, Placebo | Psoriasis | 38 | 2023-02-09actual | — | 2025-09-25 |
| Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 InflammationNCT03930732results2024-02-28Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-Week Treatment PeriodRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo | Chronic Obstructive Pulmonary Disease | 939 | 2023-02-08actual | — | 2024-02-28 |
| Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)NCT04681729results2024-02-21Percentage of Participants With Negative Ice Cube Provocation Test at Week 24Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab SAR231893, Placebo, Non sedating H1-antihistamine | Cold Urticaria | 82 | 2023-02-02actual | — | 2025-09-10 |
| A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359)NCT05235724observationalCorrelation between weekly averages of Emerald nightly scratching events/hour and Emerald derived sleep efficiency | — | Completed | — | Dermatitis Atopic | 18 | 2023-01-11actual | — | 2023-01-31 |
| Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic DrugsNCT04980027Percentage of participants with Treatment Emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 4 | Completed | Drug: Insulin glargine (U300) | Type 2 Diabetes Mellitus | 228 | 2022-12-23actual | — | 2025-09-22 |
| Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)NCT05049122results2024-01-22Percentage of Participants With NPS Improvement From Baseline >=1 at Week 24Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Dupilumab SAR231893 | Chronic Rhinosinusitis With Nasal Polyps | 25 | 2022-12-21actual | — | 2025-09-11 |
| Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma PatientsNCT05087212The proportion of patients collecting more than or equal to 6x106 CD34+ cells/kg in 2 or fewer apheresis daysOpen-label · Treatment | Phase 4 | Completed | Drug: plerixafor + G-CSF | Autologous Haematopoietic Stem Cell Transplant | 53 | 2022-12-06actual | — | 2025-09-22 |
| Efficacy and Safety of FIRTECH in Patients With Mild to Moderate Acute Low Back PainNCT05137041results2024-09-19Percentage of Numerical Rating Scale (NRS) Responders at Day 5Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Device: ITP FIRTECH | Low Back Pain | 221 | 2022-11-22actual | — | 2025-09-09 |
| Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid TumorsNCT03324113IMP-related dose limiting toxicities (DLT)Open-label · Treatment | Phase 1 | Completed | Drug: SAR408701, dexamethasone, naphazoline, diphenhydramine | Neoplasm Malignant | 34 | 2022-11-18actual | — | 2025-08-05 |
| Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in JapanNCT05132127results2023-10-03Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: sutimlimab | Cold Agglutinin Disease | 7 | 2022-11-15actual | — | 2025-09-15 |
| A Study of Isatuximab-based Therapy in Participants With LymphomaNCT03769181results2023-10-17Number of Participants With Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Study was stopped after interim analysis for all 4 cohorts with results either not fulfilling the pre-planned interim analysis criteria or fulfilling the criteria but as per sponsor decision. It was not due to any safety concern | Drug: isatuximab SAR650984, cemiplimab REGN2810 | Lymphoma | 58 | 2022-11-08actual | — | 2025-09-23 |
| Real World Study on the Use of Cemiplimab in Adult Patients in UKNCT05493826observationalOverall response rate (ORR) within 12 months post initiation of cemiplimab | — | Completed | Other: No intervention | Cutaneous Squamous Cell Carcinoma | 110 | 2022-11-01actual | — | 2023-07-14 |
| Retrospective Study on Caplacizumab-treated Pediatric Patients With Immune-mediated Thrombocytopenic Purpura (iTTP)NCT05263193observationalPlatelet count response | — | Completed | Drug: Caplacizumab | Immune-mediated Thrombocytopenic Purpura | 4 | 2022-10-28actual | — | 2022-12-14 |
| Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related ToxicityNCT05128773results2023-06-22Invasive Breast Cancer-free Survival (IBCFS)Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Sponsor decision to prematurely stop the study, not linked to any safety concern | Drug: Amcenestrant, Tamoxifen, Amcenestrant-matching placebo, Tamoxifen-matching placebo | Breast Cancer | 3 | 2022-10-13actual | — | 2025-09-16 |
| Comparative Efficacy of Cemiplimab to Historical Standard of Care in FranceNCT05302297observationalOverall Survival (OS) | — | Completed | Drug: Cemiplimab | Cancer/Squamous Cell Carcinoma of Skin | 305 | 2022-09-30actual | — | 2022-12-13 |
| Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid LeukemiaNCT03860844results2023-11-15Percentage of Participants With Complete Response (CR) RateOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not due to safety concerns. | Drug: Isatuximab, Dexamethasone or equivalent, Fludarabine, Cytarabine, Liposomal daunorubicin, Daunorubicin (nonliposomal), Idarubicin, Filgrastim or equivalent, Mitoxantrone, Doxorubicin, Vincristine, Pegaspargase (PEG) Asparaginase, Cyclophosphamide, Etoposide, Methotrexate, L - Asparginase, Hydroxyurea, L - Asparaginase (Erwinase) | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | 67 | 2022-09-12actual | — | 2025-09-09 |
| Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic DermatitisNCT04718870results2023-10-17Percent Change From Baseline in Transepidermal Water Loss (TEWL) After 5 Skin Tape Stripping (STS) on Lesional Skin (LS) in AD Participants at Week 16Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Dupilumab SAR231893 | Dermatitis Atopic | 41 | 2022-09-07actual | — | 2025-09-15 |
| First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple MyelomaNCT04000282The maximum tolerated dose (MTD) of SAR442085 (Part A)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: SAR442085 | Plasma Cell Myeloma | 37 | 2022-08-29actual | — | 2025-09-12 |
| Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.NCT05282030Assessment of PK parameters Tolebrutinib: AUCNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: tolebrutinib | Renal Impairment | 22 | 2022-08-02actual | — | 2025-02-06 |
| A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsNCT03871348For dose escalation: Incidence of Dose Limiting Toxicities (DLTs) (Monotherapy)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor terminated the study for non-safety reasons | Drug: SAR441000, Cemiplimab REGN2810 | Metastatic Neoplasm | 77 | 2022-07-25actual | — | 2025-09-10 |
| A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)NCT05797753Part A: SAR443820: Area under the plasma concentration from time zero to the last concentration above the limit of quantification (AUClast)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: SAR443820, SAR443820, Erythromycin ethyl succinate, Itraconazole | Amyotrophic Lateral Sclerosis, Healthy Volunteer | 16 | 2022-07-01actual | — | 2025-01-03 |
| Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic DermatitisNCT04823130results2023-07-11Change From Baseline in Intraepidermal Nerve Fiber Density on Lesional Skin at Week 17Non-randomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Dupilumab (SAR231893) | Dermatitis Atopic | 54 | 2022-06-30actual | — | 2025-09-16 |
| Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast CancerNCT04478266results2023-07-06Progression-free Survival (PFS)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: The study was terminated based on the review by an independent data monitoring committee of the prespecified interim analysis of the Phase 3 AMEERA-5 efficacy data. No new safety signals were observed. | Drug: Amcenestrant-matching placebo, SAR439859, Palbociclib, Letrozole, Goserelin, Letrozole-matching placebo | Breast Cancer | 1,068 | 2022-06-28actual | — | 2025-09-11 |
| A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin TherapyNCT04669041Percent change in measured LDL-C from baseline (the last available measured LDL-C value obtained up to randomization) to Week 8Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Rosuvastatin, SPC ezetimibe/rosuvastatin, Rosuvastatin active capsule, Placebo, Placebo | Hypercholesterolemia | 305 | 2022-06-15actual | — | 2025-09-22 |
| Resection ObservatoryNCT05178745observationalAssessment of resection rate (R0/R1) | — | Completed | Drug: Fluorouracil, Aflibercept, Irinotecan | Metastatic Colorectal Cancer, Colorectal Neoplasms | 140 | 2022-05-27actual | — | 2025-01-30 |
| Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic FunctionNCT05283915Assessment of PK parameters Tolebrutinib: AUCRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: tolebrutinib | Hepatic Function Abnormal | 10 | 2022-05-24actual | — | 2025-01-15 |
| Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult ParticipantsNCT06106074Part 1a and Part 2: Number of participants with Adverse Events (AEs) and treatment-emergent adverse events (TEAEs)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: Tolebrutinib, Placebo | Multiple Sclerosis | 71 | 2022-05-23actual | — | 2023-10-30 |
| Efficacy and Safety Study of Dupilumab in Patients With Persistent AsthmaNCT03782532Change in pre-bronchodilator forced expiratory volume (FEV1)Randomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Dupilumab SAR231893, Placebo, Asthma Controller Therapies (include prednisone/prednisolone), Asthma Reliever Therapies | Asthma | 486 | 2022-05-21actual | — | 2022-12-28 |
| Pharmacokinetics of Amcenestrant in Female Hepatic Impaired Participants as Compared to Participants With Normal Hepatic FunctionNCT05126329Pharmacokinetic (PK) assessment: Maximum plasma concentration observed (Cmax)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision to prematurely stop the study, not linked to any safety concern | Drug: amcenestrant | Hepatic Function Abnormal | 13 | 2022-05-16actual | — | 2025-09-22 |
| To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple SclerosisNCT03856619Adverse events (AEs)Open-label · Treatment | Phase 4 | Completed | Drug: TERIFLUNOMIDE HMR1726 | Relapsing Multiple Sclerosis | 121 | 2022-05-13actual | — | 2023-04-19 |
| Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced MalignanciesNCT03637764results2023-06-08Number of Participants With Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Study was stopped after interim analysis for 4 cohorts (HCC, SCCHN, EOC, and GBM) indicated that the results did not fulfill the preplanned interim analysis criteria to move to Phase 2 stage 2 in all 4 cohorts. | Drug: Isatuximab SAR650984, Atezolizumab | Neoplasm | 107 | 2022-05-11actual | — | 2023-07-10 |
| Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney TransplantationNCT04294459results2023-05-30Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Terminated due to non-safety reasons | Drug: Isatuximab SAR650984, Acetaminophen (paracetamol) or equivalent, Ranitidine or equivalent, Diphenhydramine or equivalent, Methylprednisolone or equivalent, Montelukast or equivalent | Immune System Disorder | 23 | 2022-05-02actual | — | 2025-09-17 |
| An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)NCT02776735results2024-10-15Maximum Serum Concentration (Cmax) of Sarilumab at Week 12Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Sarilumab | Juvenile Idiopathic Arthritis | 102 | 2022-04-08actual | — | 2024-10-15 |
| Systematic Review and Meta-Analysis of Multaq® for Safety in Atrial FibrillationNCT05279833observationalNumber of participants with Cardiovascular (CV) hospitalization | — | Completed | Drug: dronedarone, sotalol | Atrial Fibrillation | 87,810 | 2022-03-31actual | — | 2024-01-09 |
| Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic FibrosisNCT03375047results2026-02-09Parts A, B and D: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: MRT5005, Normal saline | Cystic Fibrosis | 42 | 2022-03-15actual | — | 2026-02-09 |
| Pharmacokinetic Study to Compare Itepekimab Exposure When Administered With an Autoinjector Versus Prefilled SyringeNCT06114238Assessment of pharmacokinetic (PK) parameter of itepekimab: CmaxRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Itepekimab AI, Itepekimab PFS | Chronic Obstructive Pulmonary Disease | 90 | 2022-03-08actual | — | 2024-09-19 |
| Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)NCT03620747results2023-03-16Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab SAR231893 (REGN668) | Asthma | 393 | 2022-02-18actual | — | 2023-03-16 |
| Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast CancerNCT04059484results2023-03-30Progression Free Survival (PFS)Randomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision to prematurely stop the study, not linked to any safety concern. | Drug: Amcenestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen | Breast Cancer Metastatic | 367 | 2022-02-15actual | — | 2026-02-24 |
| Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 MonthsNCT05832333observationalOccurence of solicited injection site or systemic reactions | — | Completed | Biological: VaxigripTetra® | Influenza | 682 | 2022-02-07actual | — | 2023-04-27 |
| Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate TransplantationNCT02513186Assessment of dose-limiting toxicities (DLTs) in VCDI cohortOpen-label · Treatment | Phase 1 | Completed | Drug: lenalidomide, bortezomib, cyclophosphamide, dexamethasone, isatuximab SAR650984 | Plasma Cell Myeloma | 90 | 2022-01-28actual | — | 2024-01-29 |
| Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma PatientsNCT03275285results2023-02-13Progression Free Survival (PFS) As Determined by Independent Response Committee (IRC): Primary AnalysisRandomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: isatuximab SAR650984, carfilzomib, dexamethasone | Plasma Cell Myeloma | 302 | 2022-01-14actual | — | 2026-02-09 |
| A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults SubjectsNCT05846009Number of participants with adverse events/treatment-emergent adverse events/adverse events of special interestRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: SAR442501, Placebo | Osteochondrodysplasia | 76 | 2022-01-12actual | — | 2024-08-27 |
| A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid TumorsNCT03192345Incidence of Dose Limiting Toxicities (DLTs)Randomized · Open-label · Treatment | Phase 1 | Completed | Biological: SAR439459 · Drug: Cemiplimab REGN2810 | Malignant Solid Tumor | 161 | 2021-12-21actual | — | 2024-08-07 |
| Dupilumab in Japanese Patients With Atopic DermatitisNCT04678882Proportion of participants with Eczema Area and Severity Index (EASI)-75 (≥75% improvement from baseline EASI)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Placebo, Dupilumab SAR231893 | Atopic Dermatitis | 62 | 2021-12-14actual | — | 2025-09-12 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple MyelomaNCT02514668Part A: Dose Limiting Toxicities (DLTs)Open-label · Treatment | Phase 1 | Completed | Drug: Isatuximab | Plasma Cell Myeloma | 55 | 2021-12-02actual | — | 2022-04-25 |
| Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia ANCT05042440Half-life of BIVV001Open-label · Treatment | Phase 1 | Completed | Drug: Efanesoctocog alfa, Octocog alfa, Rurioctocog alfa pegol | Hemophilia A | 13 | 2021-11-24actual | — | 2025-09-18 |
| Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)NCT04183335results2022-12-12Percentage of Participants With Improvement (Reduction) in Worst Itch Numeric Rating Scale (WI-NRS) Scores by Greater Than or Equal to (>=) 4 Points From Baseline to Week 24Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors | Neurodermatitis | 151 | 2021-11-12actual | — | 2025-09-17 |
| Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male ParticipantsNCT04982991Assessment of pharmacokinetic (PK) parameter: CmaxOpen-label · Treatment | Phase 1 | Completed | Drug: RIPK1 inhibitor | Multiple Sclerosis Healthy Subjects | 14 | 2021-10-11actual | — | 2022-04-25 |
| SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"NCT04033367results2022-11-02DB Period: Percent Change From Baseline in Sleep Quality Numerical Rating Scale (NRS) at Week 12Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Dupilumab, Placebo | Atopic Dermatitis | 188 | 2021-10-06actual | — | 2025-09-17 |
| Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy AdultsNCT05976386Maximum serum concentration of functional dupilumab (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Dupilumab (SAR231893) | Healthy Volunteers | 182 | 2021-09-24actual | — | 2025-09-19 |
| Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes PatientsNCT04075513results2022-11-14Percentage of Time of Glucose Concentration Within the Target Range of Greater Than or Equal to (>=) 70 to Less Than or Equal to (<=) 180 Milligrams Per Deciliter: Non-inferiority AnalysisRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Insulin glargine, 300 U/ml, Insulin degludec, 100U/ml, Background therapy: Rapid acting insulin analogs | Type 1 Diabetes Mellitus | 343 | 2021-09-16actual | — | 2022-11-14 |
| A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)NCT05797701Part 1: Maximum plasma concentration observed (Cmax)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: SAR443820, SAR443820 | Amyotrophic Lateral Sclerosis (Healthy Volunteers) | 18 | 2021-09-06actual | — | 2023-04-04 |
| Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)NCT04202679results2022-09-28Percentage of Participants With Greater Than or Equal to (>=) 4 Points Improvement (Reduction) From Baseline in Worst-Itch Numeric Rating Scale (WI-NRS) Scores at Week 12Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors | Neurodermatitis | 160 | 2021-08-30actual | — | 2025-09-17 |
| Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver DiseaseNCT03437720Resolution of Non-alcoholic steatohepatitis (NASH)Randomized · Quadruple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Sponsor decision to cancel TRIAL, not related to safety concern. | Drug: SAR425899, Placebo | Non-alcoholic Steatohepatitis, Type 2 Diabetes Mellitus | 0 | 2021-08-25 | — | 2022-04-13 |
| Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal WomenNCT04940026Percentage of radioactive dose, SAR439859 and M7 excreted in urine and feces after IV administrationOpen-label · Other | Phase 1 | Completed | Drug: amcenestrant, [14C]-SAR439859 microtracer, [14C]-SAR439859 | Breast Cancer, Healthy Volunteers | 6 | 2021-08-19actual | — | 2025-09-24 |
| Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.NCT04583618results2024-08-27Geometric Mean Titers (GMTs) of Pneumococcal Serotypes Using Serotype-Specific MOPARandomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb, Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI, Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII, Pneumococcal 13 - valent conjugate vaccine-Prevnar 13, Pneumococcal Vaccine Polyvalent-Pneumovax 23 | Pneumococcal Immunization | 750 | 2021-08-09actual | — | 2025-09-08 |
| Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult ParticipantsNCT05795907Parts 1a and 1b: Number of participants with adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: SAR443820, Placebo | Amyotrophic Lateral Sclerosis (Healthy Volunteers) | 84 | 2021-07-20actual | — | 2023-04-03 |
| Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With VenglustatNCT04705051results2022-10-06Percent Change in Total Kidney Volume (TKV)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: LTS15823 (long-term extension of the EFC15392 study) was stopped after protocol specified interim analysis for futility of the parent EFC15392 study met the prespecified stopping rule based on the primary outcome measure. | Drug: Venglustat GZ402671 | Congenital Cystic Kidney Disease | 24 | 2021-07-13actual | — | 2025-09-17 |
| Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 WeeksNCT04410965PK exposure: CmaxOpen-label · Treatment | Phase 4 | Completed | Drug: TERIFLUNOMIDE | Multiple Sclerosis | 82 | 2021-07-12actual | — | 2025-09-24 |
| Dupilumab Skin Barrier Function Study in Atopic DermatitisNCT04447417results2022-07-22Percent Change From Baseline in Transepidermal Water Loss After 5 Skin Tape Stripping (STS) on Lesional Skin (LS) in AD Patients at Week 16Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Dupilumab SAR231893 | Atopic Dermatitis | 52 | 2021-06-17actual | — | 2025-09-18 |
| SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM PatientsNCT02283775Dose Limiting Toxicities (DLTs)Open-label · Treatment | Phase 1 | Completed | Drug: Isatuximab SAR650984, Pomalidomide, Dexamethasone | Plasma Cell Myeloma | 54 | 2021-05-26actual | — | 2021-07-09 |
| Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia RheumaticaNCT03600818results2022-06-10Percentage of Participants Achieving Sustained Remission at Week 52Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Protracted recruitment timeline exacerbated by COVID-19 pandemic | Drug: Sarilumab SAR153191 (REGN88), Sarilumab-matching placebo, Prednisone, Prednisone-matching placebo, Prednisone | Polymyalgia Rheumatica | 118 | 2021-05-19actual | — | 2022-06-10 |
| A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)NCT04074187Proportion of participants with a recurrence of acquired thrombotic thrombocytopenic purpura (aTTP)Open-label · Treatment | Phase 2/3 | Completed | Drug: Caplacizumab (ALX-0081), Plasma exchange (PE), Corticosteroid treatment (Methylprednisolone or prednisolone), Immunosuppressive treatment (eg, rituximab) | Thrombotic Thrombocytopenic Purpura | 21 | 2021-05-19actual | — | 2025-09-22 |
| Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast CancerNCT04191382results2022-06-29Percent Change From Baseline in Ki67 Level at Day 15Randomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: early discontinuation based on strategic sponsor decision not driven by any safety concerns | Drug: Amcenestrant (SAR439859), Letrozole | Breast Cancer | 105 | 2021-04-30actual | — | 2025-09-18 |
| A National Study in Patients With Unexplained SplenomegalyNCT04430881observationalPercentage of patients diagnosed with Gaucher disease in the included population of patients with unexplained splenomegaly | — | Completed | — | Gaucher Disease, Splenomegaly | 506 | 2021-04-27actual | — | 2022-04-25 |
| Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute LeukemiaNCT04349306Incidence of AEs and SAEsOpen-label · Treatment | Phase 4 | Completed | Drug: RASBURICASE SR29142 | Lymphoma | 50 | 2021-03-12actual | — | 2022-04-25 |
| Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced MalignanciesNCT03367819results2022-05-16Number of Participants With Dose Limiting Toxicities (DLTs)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: The study was stopped after interim analysis indicated that overall result was not sufficient to satisfy per-protocol criteria to move forward in metastatic, castration-resistant prostate cancer (mCRPC) and non-small cell lung cancer (NSCLC) cohorts. | Drug: Isatuximab SAR650984, Cemiplimab REGN2810 | Prostate Cancer, Non-small Cell Lung Cancer | 44 | 2021-03-10actual | — | 2022-05-16 |
| Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)NCT03798054Change in HbA1cRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Lixisenatide (AVE0010), Metformin, SGLT2 inhibitor | Type 2 Diabetes Mellitus | 878 | 2021-03-01actual | — | 2022-07-19 |
| First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic SyndromeNCT03594955results2022-04-07Dose Escalation Part: Number of Participants With Dose Limiting Toxicities (DLTs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: SAR440234 | Leukaemia | 7 | 2021-02-06actual | — | 2022-05-24 |
| Efficacy and Safety of Teicoplanin in CDADNCT04003818Clinical cure rateOpen-label · Treatment | Phase 4 | Terminatedsponsor's stated reason: Due to COVID-19 and great challenges during patient enrolment period, current status of this study is far behind the plan. The study cannot be completed according to the plan. Sanofi decides to terminate the study upon comprehensive assessment. | Drug: TEICOPLANIN | Clostridium Difficile Infection-associated Diarrhea and Colitis | 50 | 2021-01-21actual | — | 2025-09-23 |
| An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial HypercholesterolemiaNCT03510884results2023-05-06DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) EstimandRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Alirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin, Ezetimibe, Cholestyramine, Nicotinic acid, Fenofibrate, Omega-3 fatty acids, Placebo | Hypercholesterolaemia | 153 | 2021-01-14actual | — | 2023-05-06 |
| Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)NCT01146652results2022-01-24Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: SAR153191 (REGN88) | Rheumatoid Arthritis | 2,023 | 2020-12-31actual | — | 2022-03-28 |
| Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug NaiveNCT03794336Change in Hemoglobin A1cRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: Alogliptin, Acarbose, Metformin, Aspirin | Type 2 Diabetes Mellitus | 1,293 | 2020-12-14actual | — | 2022-04-25 |
| Effect of Efpeglenatide on Cardiovascular OutcomesNCT03496298results2021-10-15Time to First Occurrence of Major Adverse Cardiovascular Events (MACE): Event Rate Per 100 Participant-years for First Occurrence of Major Cardiovascular (CV) Event - Non-Inferiority AnalysisRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Sponsor decision to cancel TRIAL, not related to safety concern | Drug: Efpeglenatide (SAR439977), Placebo | Type 2 Diabetes Mellitus | 4,076 | 2020-12-10actual | — | 2021-10-15 |
| Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal InsulinNCT03798080Change in HbA1cRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin | Type 2 Diabetes Mellitus | 426 | 2020-12-01actual | — | 2022-07-19 |
| Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With SulfonylureaNCT03770728results2021-12-02Change From Baseline to Week 30 in HbA1cRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Sponsor decision to cancel TRIAL, not related to safety concern | Drug: Efpeglenatide SAR439977, Placebo, Background therapy: Metformin alone or in combination with SU | Type 2 Diabetes Mellitus | 312 | 2020-11-28actual | — | 2021-12-02 |
| Evaluation of Efficacy and Safety of Sarilumab in Patients With GCANCT03600805results2022-01-14Percentage of Participants Who Achieved Sustained Disease Remission at Week 52Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Protracted recruitment timeline exacerbated by COVID-19 pandemic | Drug: Sarilumab SAR153191, Sarilumab matching placebo, Prednisone, Prednisone matching placebo | Giant Cell Arteritis | 83 | 2020-11-24actual | — | 2022-03-28 |
| Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)NCT03713684results2021-12-02Change From Baseline to Week 30 in HbA1cRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Sponsor decision to cancel TRIAL, not related to safety concern | Drug: Efpeglenatide SAR439977, Placebo, Background therapy | Type 2 Diabetes Mellitus | 370 | 2020-11-20actual | — | 2021-12-02 |
| Evaluation of SAR408701 in Patients With Advanced Solid TumorsNCT02187848Number of dose limiting adverse events (every 2 week cycle)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision, The decision is not related to any safety concern. | Drug: SAR408701 | Neoplasm Malignant | 254 | 2020-11-10actual | — | 2025-02-10 |
| Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of AgeNCT04368429results2021-10-06Percentage of Participants With Vaccine Seroresponse For Meningococcal Serogroup A, C, Y And W Following Vaccination With MenACYW Conjugate and Menactra® Vaccine: Non-Inferiority AnalysisRandomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine), Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine | Meningococcal Immunisation (Healthy Volunteers) | 360 | 2020-11-07actual | — | 2025-09-15 |
| Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)NCT03816839Investigational medicinal product (IMP)-related dose limiting toxicities (DLTs)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision to prematurely stop the study, not linked to any safety concern. | Drug: Amcenestrant (SAR439859) | Breast Cancer | 10 | 2020-10-27actual | — | 2025-07-07 |
| Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)NCT02878603results2021-11-22Percentage of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Related EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: Caplacizumab · Other: Standard of Care | Acquired Thrombotic Thrombocytopenic Purpura | 104 | 2020-10-23actual | — | 2022-03-28 |
| Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)NCT03767543Change in glycated hemoglobin (HbA1c)%Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010 | Type 2 Diabetes Mellitus | 265 | 2020-10-23actual | — | 2022-04-25 |
| A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19NCT04469621Relative change from baseline in CRP levelRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: SAR443122, Placebo | Corona Virus Infection | 68 | 2020-10-23actual | — | 2025-09-23 |
| Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With MetforminNCT03684642results2021-11-01Change From Baseline to Week 56 in HbA1cRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Sponsor decision to cancel TRIAL, not related to safety concern. | Drug: Efpeglenatide, Dulaglutide, Background therapy Metformin | Type 2 Diabetes Mellitus | 908 | 2020-10-13actual | — | 2021-11-01 |
| Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of InsulinNCT03760991Change in glycated hemoglobin (HbA1c)Open-label · Treatment | Phase 4 | Completed | Drug: INSULIN GLARGINE (U300) | Type 2 Diabetes Mellitus | 372 | 2020-09-23actual | — | 2022-04-25 |
| Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple MyelomaNCT03733717Assessment of PK: CmaxOpen-label · Treatment | Phase 1 | Completed | Drug: Isatuximab SAR650984 | Multiple Myeloma | 25 | 2020-09-06actual | — | 2023-09-08 |
| Evaluation of Dupilumab in Children With Uncontrolled AsthmaNCT02948959results2021-10-20Annualized Rate of Severe Exacerbation Events During the 52-Week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter PopulationRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab, Placebo, Asthma Controller Therapies, Asthma Reliever Therapies | Asthma | 408 | 2020-08-26actual | — | 2022-03-28 |
| A Study of the Safety, Tolerability, and Bioavailability of Orally Administered Venglustat in Healthy Adult ParticipantsNCT06418620Maximum plasma concentration observed (Cmax) of venglustatRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Venglustat | Healthy Volunteers | 9 | 2020-08-07actual | — | 2024-05-17 |
| Sarilumab COVID-19NCT04327388results2021-05-13Time to Improvement in Clinical Status of Participants (Using 7-point Ordinal Scale Score) by at Least 2 PointsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Sarilumab SAR153191, Placebo | Corona Virus Infection | 420 | 2020-07-31actual | — | 2025-09-24 |
| A Study of the Safety, Tolerability, and Bioequivalence of Orally Administered Venglustat in Healthy Adult ParticipantsNCT06418607Maximum plasma concentration observed (Cmax) of venglustatRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Venglustat, Venglustat | Healthy Volunteers | 65 | 2020-07-13actual | — | 2024-05-17 |
| Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin GlargineNCT03874715results2023-07-21Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Measurable Timepoint (AUClast) of Insulin Aspart Following Administration of Either SAR341402 (Switching Arm) or NovoLog (Non-switching Arm)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Insulin Aspart SAR341402, Insulin Aspart, Insulin glargine U100 | Type 1 Diabetes Mellitus | 210 | 2020-07-08actual | — | 2024-04-17 |
| Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult SubjectsNCT06064539Pharmacokinetics: AUClast of SAR442168Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Tolebrutinib, gemfibrozil, rifampicin | Multiple Sclerosis | 30 | 2020-07-08actual | — | 2025-09-17 |
| Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin TherapyNCT03359837Change in hemoglobin A1c (HbA1c)Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: INSULIN GLARGINE (HOE901), Insulin Glulisine, Biphasic insulin aspart 30, Repaglinide, Acarbose, Metformin | Type 2 Diabetes Mellitus | 384 | 2020-06-29actual | — | 2022-04-25 |
| Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral SclerosisNCT03757351Number of Subjects with Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Randomized · Double-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Due to change in Sanofi's development strategy for DNL747/SAR443060 - not due to any safety concerns | Drug: DNL747, Placebo | Amyotrophic Lateral Sclerosis | 15 | 2020-06-18actual | — | 2025-09-22 |
| Hydroxychloroquine in Outpatient Adults With COVID-19NCT04333654Change from baseline to Day 3 in nasopharyngeal SARS-CoV-2 viral load (if quantitative PCR is available)Randomized · Quadruple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Rate of enrollment too slow to allow completion in a reasonable timeframe | Drug: Hydroxychloroquine SAR321068, Placebo | Coronavirus Infection | 8 | 2020-05-26actual | — | 2025-09-23 |
| Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without SulfonylureaNCT03761134Change in hemoglobin A1c (HbA1c)Randomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Sanofi ended collaboration with Lexicon for Sotagliflozin. In China no regulatory pathway to transfer sponsorship during the conduct of ongoing studies. | Drug: sotagliflozin (SAR439954), placebo, metformin, sulfonylurea | Type 2 Diabetes Mellitus | 377 | 2020-04-29actual | — | 2022-04-25 |
| Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and ExerciseNCT03760965Change in hemoglobin A1c (HbA1c)Randomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Sanofi ended collaboration with Lexicon for Sotagliflozin. In China no regulatory pathway to transfer sponsorship during the conduct of ongoing studies. | Drug: sotagliflozin (SAR439954), placebo | Type 2 Diabetes Mellitus | 276 | 2020-04-24actual | — | 2022-04-25 |
| Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult SubjectsNCT05845996Part 1: Number of participants with adverse event(AE)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: SAR441344, placebo · Biological: Keyhole limpet hemocyanin | Healthy Volunteers | 56 | 2020-04-10actual | — | 2025-09-16 |
| An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial HypercholesterolemiaNCT03510715results2020-12-29Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12: Intent-to-Treat (ITT) AnalysisOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Alirocumab SAR236553 (REGN727), Atorvastatin, Simvastatin, Fluvastatin, Pravastatin, Lovastatin, Rosuvastatin, Ezetimibe, Cholestyramine, Nicotinic acid, Fenofibrate, Omega-3 fatty acids | Hypercholesterolemia | 18 | 2020-02-17actual | — | 2020-12-29 |
| Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic DermatitisNCT03912259results2021-04-05Number of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of Greater Than or Equal to (>=) 2 Points at Week 16Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab, Placebo, Emollient (moisturizer) | Atopic Dermatitis | 165 | 2020-02-14actual | — | 2023-12-19 |
| A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)NCT02803918Number of patients with adverse events (AEs)Randomized · Single-masked · Treatment | Phase 1 | Completed | Drug: Lixisenatide (AVE0010), Placebo, Basal Insulin, Metformin | Type 2 Diabetes Mellitus | 23 | 2020-01-27actual | — | 2022-04-25 |
| Dose-finding Study for SAR442168 in Relapsing Multiple SclerosisNCT03889639results2023-03-08Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New Gadolinium (Gd) Enhancing T1-hyperintense LesionsRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: SAR442168, Placebo, Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI) | Relapsing Multiple Sclerosis | 130 | 2020-01-02actual | — | 2025-09-17 |
| Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male SubjectsNCT04171310Percentage of radioactive dose excreted in urine and fecesOpen-label · Treatment | Phase 1 | Completed | Drug: SAR442168 | Multiple Sclerosis | 6 | 2019-12-30actual | — | 2025-09-23 |
| Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and AboveNCT05406180observationalNumber of participants with solicited injection site or systemic reactions | — | Completed | Biological: VaxigripTetra inj. | Influenza | 675 | 2019-12-27actual | — | 2022-06-06 |
| Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)NCT03529123Change in HbA1cRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010), INSULIN GLARGINE (HOE901), Metformin, Insulin Glulisine (HMR1964) | Type 2 Diabetes Mellitus | 247 | 2019-11-25actual | — | 2022-04-25 |
| A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney TransplantNCT03099122Percentage of patients with biopsy-proven acute rejection eventsOpen-label · Prevention | Phase 4 | Completed | Biological: Rabbit Anti-thymocyte Immunoglobulin · Drug: Tacrolimus, Methylprednisolone, Mycophenolate mofetil, Mycophenolate Na, prednisone | End-stage Renal Disease | 115 | 2019-11-12actual | — | 2022-04-25 |
| Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum MalariaNCT03660839results2020-12-02Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 28 (ACPR28)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Artefenomel (OZ439), Ferroquine (SSR97193) | Plasmodium Falciparum Infection | 140 | 2019-11-06actual | — | 2022-03-21 |
| Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)NCT02134028results2020-11-02Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab | Asthma | 2,282 | 2019-10-11actual | — | 2022-03-28 |
| Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)NCT03546907results2022-11-22Annualized Rate of Moderate to Severe Acute Exacerbation Events in Chronic Obstructive Pulmonary Disease (AECOPD) ParticipantsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: SAR440340, Placebo, Any Inhaled Corticosteroids as prescribed by treating physician as standard of care, Any Long Acting Beta Agonist as prescribed by treating physician as standard of care, Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care, Any short-acting β agonist as prescribed by treating physician as standard of care | Chronic Obstructive Pulmonary Disease | 343 | 2019-10-03actual | — | 2022-11-22 |
| Acne Vulgaris Related Microbiology and SerologyNCT04056598observationalCorrelation of acne vulgaris severity with humoral immunity assessed by ELISA, binding to P. acnes strains and OPK assay | — | Completed | Diagnostic test: Study of humoral immunity | Acne Vulgaris | 120 | 2019-09-30actual | — | 2021-01-06 |
| First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight SubjectsNCT04521738Number of participants with adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: SAR441255, placebo | Overweight, Healthy Subjects | 48 | 2019-09-26actual | — | 2025-09-22 |
| To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum MalariaNCT02497612results2020-10-19Percentage of Participants With Polymerase Chain Reaction (PCR)-Adjusted Adequate Clinical and Parasitological Response (ACPR) at Day 28: African <=5 Years Per Protocol Population at Day 28 (PP28)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: All treatment arms met the futility criteria for efficacy during the pre-planned interim analysis, therefore the study was stopped. | Drug: Ferroquine SSR97193, Artefenomel · Other: Placebo | Plasmodium Falciparum Infection | 377 | 2019-09-23actual | — | 2022-03-24 |
| A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 DiabetesNCT03903016Assessment of pharmacokinetc (PK) parameter:INS-CmaxRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Insulin Lispro SAR342434, Insulin Lispro SAR342434 | Type 1 Diabetes | 90 | 2019-08-19actual | — | 2025-09-24 |
| Sotagliflozin Multiple-dose Study in Healthy Chinese SubjectsNCT03909451Adverse events (AEs)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: Sotagliflozin (SAR439954), Placebo | Diabetes Mellitus | 24 | 2019-08-19actual | — | 2022-04-25 |
| Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular DegenerationNCT01367444results2020-06-05Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Study stopped not for safety reasons. Due to review of clinical development plans and priorities, Sponsor decided to stop development of the product. | Drug: SAR422459 | Stargardt's Disease | 27 | 2019-08-16actual | — | 2022-04-14 |
| Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1BNCT01505062results2020-03-18Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Study stopped not for safety reasons. Due to review of clinical development plans and priorities, Sponsor decided to stop development of the product. | Drug: SAR421869 | Usher Syndrome, Retinitis Pigmentosa | 9 | 2019-08-16actual | — | 2022-04-28 |
| Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In ChinaNCT03001011results2020-07-28Change From Baseline in Serum Phosphorus at Week 8Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Placebo, Sevelamer Carbonate (GZ419831) | Hyperphosphatemia | 202 | 2019-08-16actual | — | 2022-03-25 |
| Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid ArthritisNCT03449758results2020-08-10Change From Baseline in Rheumatoid Arthritis Impact of Disease Total Score at Week 24Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: SARILUMAB, Azathioprine, Chloroquine, Hydroxychloroquine, Leflunomide, Methotrexate, Sulfasalazine | Rheumatoid Arthritis | 84 | 2019-07-31actual | — | 2022-04-28 |
| Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost.NCT03703869observationalChange in HbA1c at month 6 | — | Completed | Drug: Insulin glargine (U300) | Diabetes | 4,589 | 2019-06-28actual | — | 2022-04-25 |
| A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent PatientsNCT03463135Adverse events (AEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Glucopyranosyl Lipid A (GLA), Sublingual Immuno Therapy (SLIT) Peanut Extract (PE), Placebo for GLA, Placebo for SLIT PE | Food Allergy | 27 | 2019-05-08actual | — | 2022-04-25 |
| A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted ConditionsNCT03776227CmaxRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: sotagliflozin (SAR439954) | Type 2 Diabetes Mellitus, Healthy Subjects | 66 | 2019-04-22actual | — | 2022-04-25 |
| Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate HypertensionNCT03462069Assessment of pharmacodynamic (PD) parameters in fecesRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Sotagliflozin (SAR439954), Placebo, Empagliflozin, Placebo | Diabetes Mellitus | 41 | 2019-04-18actual | — | 2022-04-25 |
| Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)NCT02476006results2020-03-30Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: ALIROCUMAB SAR236553 (REGN727), placebo (for injection training only), ezetimibe, atorvastatin, rosuvastatin, simvastatin | Hypercholesterolemia | 998 | 2019-04-12actual | — | 2022-03-28 |
| Study of Excretion Balance and Pharmacokinetics of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal or Permanently Sterile Female SubjectsNCT03681158Percentage of radioactive dose excreted in urine and fecesOpen-label · Treatment | Phase 1 | Completed | Drug: sodium valproate | Epilepsy | 5 | 2019-04-11actual | — | 2022-04-25 |
| Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female SubjectsNCT03802487Pharmacokinetic (PK) parameter: Absolute Bioavailability (F)Open-label · Treatment | Phase 1 | Completed | Drug: Sotagliflozin (SAR439954), 14C-microtracer, Charcoal | Type 2 Diabetes Mellitus, Healthy Subjects | 6 | 2019-03-28actual | — | 2022-04-25 |
| Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted AgentNCT02485691results2022-02-14Radiographic Progression-Free Survival (rPFS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: cabazitaxel XRP6258, enzalutamide, abiraterone acetate, prednisone | Prostate Cancer Metastatic | 255 | 2019-03-27actual | — | 2022-05-27 |
| Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma ParticipantsNCT03387852results2022-03-29Percentage of Participants With Loss of Asthma ControlRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination, Placebo for SAR440340, Placebo for dupilumab | Asthma | 296 | 2019-03-21actual | — | 2022-06-14 |
| Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mLNCT03406000Mean change in HbA1cOpen-label · Treatment | Phase 4 | Completed | Drug: INSULIN GLARGINE (U300) | Type I Diabetes Mellitus | 170 | 2019-02-04actual | — | 2022-04-25 |
| Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric CancerNCT01515748results2020-03-02Percentage of Participants With 3-Year Progression-Free Survival (PFS), as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)1.1Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Docetaxel (XRP6976), Oxaliplatin (SR96669), S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil) | Gastric Cancer | 530 | 2019-01-21actual | — | 2023-12-13 |
| Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic SclerosisNCT02921971results2022-02-02Change From Baseline in Modified Rodnan Skin Score to Week 24Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: SAR156597, Placebo | Systemic Sclerosis | 97 | 2019-01-14actual | — | 2022-03-21 |
| Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic AgentsNCT03434119results2020-01-13Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: ("Trial terminated (recruitment delays)") | Drug: Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy | Type 2 Diabetes Mellitus | 241 | 2019-01-07actual | — | 2022-03-28 |
| Study Evaluating the Efficacy and Safety of Fexofenadine in Subjects Suffering From Seasonal Allergic Rhinitis in Presence of PollutantsNCT03664882Total nasal symptom score (TNSS)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Fexofenadine M016455, Placebo | Rhinitis Seasonal | 240 | 2019-01-03actual | — | 2022-04-25 |
| A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese SubjectsNCT03376802Sleep energy expenditureRandomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: SAR425899, Placebo | Type 2 Diabetes Mellitus | 24 | 2018-12-27actual | — | 2022-04-25 |
| Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes MellitusNCT03462017Change in Flow Mediated Dilation (FMD)Randomized · Triple-masked · Basic science | Phase 1 | Completed | Drug: SAR247799, Placebo, Sildenafil, Acetylcholine | Microvascular Coronary Artery Disease | 54 | 2018-12-22actual | — | 2022-04-25 |
| Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological MalignanciesNCT01084252results2020-04-15Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Isatuximab SAR650984, Dexamethasone, Dexamethasone | Hematological Malignancy | 351 | 2018-12-21actual | — | 2024-11-01 |
| Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma PatientsNCT02990338results2019-12-06Progression Free Survival (PFS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Isatuximab, Pomalidomide, Dexamethasone | Plasma Cell Myeloma | 307 | 2018-11-22actual | — | 2025-01-17 |
| Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)NCT03260868results2020-01-07Change From Baseline in Glycated Hemoglobin A1c (HbA1c) to Week 24Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Terminatedsponsor's stated reason: Due to "prolonged low participant recruitment" | Drug: Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra) | Type 1 Diabetes Mellitus | 15 | 2018-11-22actual | — | 2022-04-07 |
| Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus PatientsNCT03436498Infusion set occlusionsRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Insulin aspart SAR341402, Insulin aspart | Type 1 Diabetes Mellitus | 45 | 2018-10-06actual | — | 2022-04-25 |
| A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension PeriodNCT03414736Frequency of gastrointestinal (GI) adverse events (AEs)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: SAR425899 | Type 2 Diabetes Mellitus | 60 | 2018-10-05actual | — | 2022-04-25 |
| Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic DrugsNCT02752412Change from baseline in HbA1cRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010), Insulin glargine U100 (HOE901), Metformin | Type 2 Diabetes Mellitus | 513 | 2018-10-04actual | — | 2020-06-16 |
| An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial HypercholesterolemiaNCT02890992results2019-09-06Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: alirocumab SAR236553 (REGN727), statins, ezetimibe, cholestyramine, fenofibrate, omega-3 fatty acids, nicotinic acid | Hypercholesterolaemia | 42 | 2018-09-13actual | — | 2019-09-06 |
| Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast CancerNCT02984683results2021-09-08Number of Participants With Investigational Medicinal Product (IMP)-Related Predefined Safety Criteria FindingsRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Study discontinued considering the limited clinical benefit combined with a higher than expected rate of known non-serious ophthalmological event. | Drug: SAR566658 (ACT14884) | Triple Negative Breast Cancer | 23 | 2018-09-07actual | — | 2021-09-08 |
| Efficacy and Safety Study of New Ambroxol Hardboiled Lozenges in Acute PharyngitisNCT03583658Change in pain intensity difference (PID)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: ambroxol BIH1526, placebo | Pharyngitis | 390 | 2018-09-02actual | — | 2022-04-25 |
| Controlled Clinical Study of Dupilumab in Patients With Nasal PolypsNCT02898454results2019-10-23Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity ScoreRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate nasal spray | Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) | 448 | 2018-08-27actual | — | 2019-10-23 |
| Association of Type 1 Diabetes Mellitus in Offsprings With Positive Parental History of DiabetesNCT03312478Odds of Type 1 Diabetes Mellitus child having a diabetic parentNon-randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Blood draw for insulin auto-anti body tests* | Type 1 Diabetes | 375 | 2018-08-19actual | — | 2022-04-25 |
| Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying TherapyNCT03415178results2019-09-09Percentage of SYDNEY-Associated Product Technical Complaints (PTCs) (Overall) at the Unsupervised Injections: Single-Arm PeriodRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Alirocumab SAR236553, Atorvastatin, Rosuvastatin · Device: Current auto-injector device (AI), New auto-injector device (SYDNEY) | Hypercholesterolaemia | 69 | 2018-08-09actual | — | 2019-09-09 |
| Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With HypercholesterolemiaNCT02715726results2019-09-30Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: Intent-to-treat (ITT) AnalysisRandomized · Quadruple-masked · TreatmentStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 3 | Completed | Drug: Alirocumab, Placebo for alirocumab, ezetimibe, placebo for ezetimibe, atorvastatin, rosuvastatin, simvastatin | Hypercholesterolemia | 615 | 2018-08-06actual | — | 2019-09-30 |
| Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic TherapyNCT02855684Change in HbA1c from baselineRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Insulin glargine (U300), Insulin glargine, Non-insulin antihyperglycemic drugs | Type 2 Diabetes Mellitus | 604 | 2018-08-06actual | — | 2022-04-25 |
| Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma PatientsNCT02812706results2024-04-01Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Isatuximab SAR650984 | Multiple Myeloma | 36 | 2018-07-31actual | — | 2024-04-01 |
| Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With HypercholesterolemiaNCT02984982results2019-09-09Percent Change From Baseline in Normalized Total Atheroma Volume (TAV) at Week 36Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Alirocumab SAR236553, Atorvastatin, Rosuvastatin, Fenofibrate, Bezafibrate, Ezetimibe, Antiplatelets, Anticoagulants | Hypercholesterolemia, Acute Coronary Syndrome | 206 | 2018-07-27actual | — | 2019-09-09 |
| A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCINCT03236311results2019-07-11Change From Baseline in Uncorrected Global Coronary Flow Reserve (CFR) at Week 4Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: (Recruitment was early terminated due to slow recruitment. Not linked to any safety concern.) | Drug: SAR407899, Placebo, Adenosine, Regadenoson, 13N-ammonia, 82Rubidium | Microvascular Coronary Artery Disease | 10 | 2018-07-23actual | — | 2022-03-24 |
| Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin GlargineNCT03211858results2019-08-08Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Insulin aspart, NovoLog/NovoRapid, Insulin glargine (HOE901) | Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus | 597 | 2018-07-16actual | — | 2022-03-28 |
| Observational Study Describing the Immune Profile Induced By Pertussis VaccinesNCT03147898observationalAnti Pertussis antibody concentrations pre and post vaccination | — | Completed | — | Whooping Cough, Pertussis | 90 | 2018-07-09actual | — | 2022-04-25 |
| A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal PolypsNCT02912468results2019-07-25Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity ScoreRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate 50 micrograms | Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) | 276 | 2018-07-05actual | — | 2019-07-25 |
| A Study of SAR428926 in Patients With Advanced Solid TumorsNCT02575781Number of patients with dose limiting adverse events (Escalation cohort)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: SAR428926 | Neoplasm Malignant | 34 | Jun 2018actual | — | 2018-08-22 |
| A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus PatientsNCT03350191Glucagon receptor occupancyNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: SAR425899, [68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer), [68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer) | Type 2 Diabetes Mellitus | 13 | 2018-06-07actual | — | 2022-04-25 |
| Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes MellitusNCT02735044results2019-06-19Change From Baseline in HbA1c to Month 6Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Insulin glargine,300 U/mL, Insulin glargine (100 units /mL), Background therapy | Type 1 Diabetes Mellitus | 463 | 2018-05-31actual | — | 2022-03-25 |
| Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in JapanNCT02749890Change from baseline in HbA1cRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010), Lixisenatide (AVE0010), Oral anti-diabetic drugs | Type 2 Diabetes Mellitus | 321 | May 2018actual | — | 2020-06-16 |
| Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension PeriodNCT02787551results2019-06-12Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 26: Core PeriodRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor) | Type 2 Diabetes Mellitus | 514 | 2018-05-25actual | — | 2022-03-25 |
| Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination RegimenNCT01587040results2019-06-11Number of Participants With Treatment Emergent Adverse Events (TEAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: SAR245408, SAR245409 | Neoplasm Malignant | 61 | 2018-05-23actual | — | 2022-04-19 |
| Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 YearsNCT03344029Summary of Geometric Mean Titers (GMTs) of Each of the Three Strains of TIV Antibodies Following a Single Dose of SP Shz TIV or Hualan TIVRandomized · Triple-masked · Prevention | Phase 4 | Completed | Biological: SP Shz TIV, Hualan TIV | Influenza, Flu | 1,600 | 2018-05-22actual | — | 2022-04-25 |
| A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple SclerosisNCT02977533Number of participants with treatment emergent adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: GZ402668, Placebo, Acyclovir | Progressive Multiple Sclerosis | 20 | 2018-05-16actual | — | 2022-04-25 |
| Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or EnzalutamideNCT02379390results2019-06-21Radiographic Progression-Free Survival (rPFS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Unsatisfactory patient accrual | Drug: Cabazitaxel XRP6258, Ezalutamide, Abiraterone acetate, Prednisone | Prostate Cancer Metastatic | 8 | 2018-05-10actual | — | 2019-06-21 |
| Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)NCT02836704Percentage of patients with at least one episode of hypoglycemiaRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: INSULIN GLARGINE, metformin, acarbose | Diabetes Mellitus, Type 2 | 892 | 2018-04-26actual | — | 2022-04-25 |
| Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)NCT02545842Percentage of patients with HbA1c <7% achievementRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: INSULIN GLARGINE | Type 2 Diabetes Mellitus | 947 | 2018-04-20actual | — | 2022-04-25 |
| Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and HypertensionNCT02842359Change from baseline in flow mediated dilatationRandomized · Open-label · Treatment | Phase 4 | Completed | Drug: Irbesartan/atorvastatin fixed dose combination, Irbesartan SR47436, Atorvastatin | Type 2 Diabetes Mellitus | 11 | 2018-04-19actual | — | 2022-04-13 |
| A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor MetabolizersNCT06188325Pharmacokinetic (PK) parameter: CmaxRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Eliglustat | Gaucher's Disease | 18 | 2018-03-26actual | — | 2024-01-10 |
| Comparison of Exposure and Activity of SAR341402 Mix 70/30 to NovoLog Mix 70/30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes MellitusNCT03916601(Cohort 1) Assessment of PK parameter: Maximum insulin concentration (INS-Cmax)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: SAR341402, Insulin Aspart, Insulin Aspart, SAR341402 | Type 1 Diabetes | 52 | 2018-03-22actual | — | 2022-04-25 |
| Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in JapanNCT02752828Change from baseline in HbA1cRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Oral anti-diabetic drugs | Type 2 Diabetes Mellitus | 521 | 2018-03-12actual | — | 2020-06-16 |
| A Drug-Drug Interaction Study Between Sotagliflozin and RamiprilNCT03414723Assessment of PK parameter: AUCtauOpen-label · Basic science | Phase 1 | Completed | Drug: Sotagliflozin (SAR439954), Ramipril | Diabetes Mellitus, Healthy Subjects | 16 | 2018-03-10actual | — | 2022-04-25 |
| Phase 1 Safety Testing of SAR405838NCT01636479SAR405838 Maximum tolerated dose (MTD)Open-label · Treatment | Phase 1 | Completed | Drug: SAR405838 | Neoplasm Malignant | 77 | 2018-03-05actual | — | 2018-05-17 |
| A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)NCT02451137results2019-05-01Percentage of Participants With Individualized Glycated Hemoglobin Target Attainment Per Healthcare Effectiveness Data and Information Set (HEDIS) Criteria Without Documented Symptomatic(Blood Glucose <=70 mg/dL [<=3.9 mmol/L]) and/or Severe HypoglycemiaRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Insulin glargine, 300 U/ml, Insulin glargine, 100 U/ml, Insulin detemir, Background Therapy | Diabetes Mellitus, Type 2 | 3,304 | 2018-03-02actual | — | 2019-09-10 |
| A Drug to Drug Interaction Study of Sotagliflozin With HydrochlorothiazideNCT03387657Assessment of PK parameter: AUCtauOpen-label · Treatment | Phase 1 | Completed | Drug: Sotagliflozin (SAR439954), Hydrochlorothiazide | Type 2 Diabetes Mellitus | 16 | 2018-03-02actual | — | 2022-04-25 |
| Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 DiabetesNCT01194882Refill accuracy between the 2 insulin groupsRandomized · Single-masked · Treatment | Phase 3 | Completed | Drug: HUMAN INSULIN (BIOSYNTHETIC), Insuplant | Diabetes Mellitus, Type 1 | 479 | 2018-02-01actual | — | 2018-02-15 |
| Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration TrialNCT00995293Progression-free survivalRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: DOCETAXEL, CISPLATIN, 5-FLUOROURACIL | Head and Neck Neoplasms | 240 | 2018-01-26actual | — | 2018-03-02 |
| ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With AlirocumabNCT01663402results2019-03-18Time to First Occurrence of Major Adverse Cardiovascular Event (MACE); Percentage of Observed Participants With Outcome Measure Events During the StudyRandomized · Double-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Alirocumab, Placebo, LMT | Atherosclerotic Cardiovascular Disease | 18,924 | 2018-01-23actual | — | 2019-03-18 |
| Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With AsthmaNCT02573233results2019-01-28Change From Baseline in Eosinophils Cells Count in the Bronchial Submucosa at Week 12Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol | Asthma | 42 | 2018-01-03actual | — | 2022-04-04 |
| A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes MellitusNCT02973321results2021-02-09Change From Baseline in HbA1c to Week 26Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: SAR425899, Placebo, Liraglutide, Metformin | Type 2 Diabetes Mellitus | 296 | 2017-12-27actual | — | 2022-03-24 |
| A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in TurkeyNCT02954692Mean change from baseline in HbA1cOpen-label · Treatment | Phase 4 | Completed | Drug: INSULIN GLARGINE (U300), metformin, sulfonylurea, meglitinides, thiazolidinediones, alpha-glucosidase inhibitors, GLP1 Receptor Agonist, Dipeptidyl peptidase-IV (DPP-IV) inhibitors, Sodium-glucose transport-2 (SGLT-2) inhibitors | Type 2 Diabetes Mellitus | 112 | 2017-12-22actual | — | 2019-01-14 |
| Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy SubjectsNCT03310944Assessment of Pharmacokinetic (PK) Parameter: AUCRandomized · Open-label · Health services research | Phase 1 | Completed | Drug: sotagliflozin (SAR439954) | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 12 | 2017-12-08actual | — | 2022-04-13 |
| Treatment of Type 2 Diabetes With Long Acting Basal Insulin in JordanNCT02606357Change from baseline in HbA1cOpen-label · Treatment | Phase 4 | Completed | Drug: INSULIN GLARGINE | Diabetes Mellitus, Type 2 | 242 | 2017-11-27actual | — | 2018-10-12 |
| A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese SubjectsNCT02979015Incidence of adverse events based on standard and systematic assessment including physical examinations, 12 lead ECGs, vital signs and laboratory testsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: alirocumab SAR236553 (REGN727), placebo | Hypercholesterolemia | 35 | 2017-11-27actual | — | 2017-12-05 |
| Safety and Efficacy of Isatuximab in Lymphoblastic LeukemiaNCT02999633results2020-01-18Percentage of Participants With Objective ResponseOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Due to an unsatisfactory benefit/risk ratio, as specified in \& 14.8.1 of the protocol, Sanofi decided to stop enrollment and terminate ACT14596 prematurely | Drug: Isatuximab SAR650984, dexamethasone, dexamethasone, acetaminophen, ranitidine, diphenhydramine | T-cell Type Acute Leukemia-Precursor, T-lymphoblastic Lymphoma/Leukaemia | 14 | 2017-11-14actual | — | 2022-03-21 |
| Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast CancerNCT02664103Proportion of patients with adverse eventsRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: Fixed-dose combination of capecitabine and cyclophosphamide SAR439281 | Breast Cancer Metastatic | 2 | 2017-11-06actual | — | 2018-02-01 |
| A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal InsulinNCT02967211Change in HbA1c (percentage %)Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: insulin glargine (U300), insulin glargine (U100), NPH insulin, insulin detemir, insulin degludec | Diabetes Mellitus, Type 2 | 609 | 2017-10-20actual | — | 2022-04-25 |
| A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating InsulinNCT02967224Change in HbA1c (percentage %)Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: insulin glargine (U300), insulin glargine (U100), NPH insulin, insulin detemir, insulin degludec | Diabetes Mellitus, Type 2 | 705 | 2017-10-16actual | — | 2022-04-25 |
| Evaluation of Dupilumab in Patients With Severe Steroid Dependent AsthmaNCT02528214results2018-10-23Percentage Reduction From Baseline in Oral Corticosteroids (OCS) Dose at Week 24 While Maintaining Asthma ControlRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab, Placebo, Oral corticosteroid therapy (prednisone/prednisolone), Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol | Asthma | 210 | 2017-09-20actual | — | 2019-10-01 |
| A Study to Evaluate the Effect of Food on the Pharmacokinetics of Sotagliflozin and to Explore the Relative Bioavailability in Healthy SubjectsNCT03174548Maximum plasma drug concentration (Cmax) of sotagliflozinRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Sotagliflozin (SAR439954), Sotagliflozin (SAR439954) | Diabetes Mellitus | 14 | 2017-09-15actual | — | 2022-04-25 |
| Sotagliflozin Bioequivalence StudyNCT03211195Assessment of PK (pharmacokinetic) parameter: CmaxRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Sotagliflozin (SAR439954) | Type 2 Diabetes Mellitus | 76 | 2017-08-22actual | — | 2022-04-25 |
| Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor AgonistNCT02738151results2018-09-14Change From Baseline in HbA1c to Week 24Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Insulin glargine, 300U/mL, Insulin degludec, 100 U/mL, Non-insulin anti-diabetic treatment | Diabetes Mellitus, Type 2 | 929 | 2017-08-15actual | — | 2018-09-14 |
| Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During RamadanNCT02941367Percentage of patients with at least 1 documented symptomatic hypoglycemia event (plasma glucose ≤70 mg/dL; 3.9 mmol/L)Randomized · Open-label · Treatment | Phase 4 | Completed | Drug: Lixisenatide (AVE0010), Sulfonylurea, metformin, basal insulin | Diabetes Mellitus, Type 2 | 184 | 2017-08-04actual | — | 2022-04-25 |
| Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)NCT02414854results2018-10-23Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: Intent-to-Treat (ITT) PopulationRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Dupilumab, Placebo, Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol | Asthma | 1,902 | 2017-07-29actual | — | 2018-10-23 |
| Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin TreatmentNCT02967237Mean change from baseline in HbA1cOpen-label · Treatment | Phase 4 | Completed | Drug: insulin glargine (U300) | Diabetes Mellitus, Type 2 | 136 | 2017-07-24actual | — | 2022-04-25 |
| A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B PatientsNCT02035605The safety of ALN-AT3SC evaluated by the proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs), dose-limiting toxicities (DLTs), and AEs leading to study drug discontinuation.Randomized · Single-masked · Treatment | Phase 1 | Completed | Drug: ALN-AT3SC, Sterile Normal Saline (0.9% NaCl) | Hemophilia A, Hemophilia B | 51 | 2017-07-20actual | — | 2020-12-19 |
| A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR)NCT03317015Change from baseline in total nasal symptom scoreRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: triamcinolone XRG5029, fluticasone | Rhinitis Allergic | 260 | 2017-07-10actual | — | 2022-04-25 |
| Study to Evaluate Improvements of the Quality of Sleep With NOVANUIT® Triple Action in Healthy Volunteers With Sleep DisordersNCT03514732Comparison of the sleep qualityNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: MELATONIN (MELATL07959) | Sleep Disorder (Healthy Volunteers) | 40 | 2017-07-05actual | — | 2022-04-25 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19